<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_xTRwAQn">Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer&apos;s disease</title>
				<funder ref="#_7FkCyhN">
					<orgName type="full">Chercheur Boursier</orgName>
				</funder>
				<funder ref="#_gQuD3jx">
					<orgName type="full">National Academy of Neuropsychology</orgName>
					<orgName type="abbreviated">NAN</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100011471</idno>
				</funder>
				<funder ref="#_sN5EW2D">
					<orgName type="full">National Institutes of Health</orgName>
					<orgName type="abbreviated">NIH</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000002</idno>
				</funder>
				<funder ref="#_A7mgMrk">
					<orgName type="full">CNPq</orgName>
				</funder>
				<funder>
					<orgName type="full">Erling-Persson Family Foundation</orgName>
				</funder>
				<funder ref="#_yseP4zd">
					<orgName type="full">Hjärnfonden, Sweden</orgName>
				</funder>
				<funder ref="#_Sam8wrp #_BV2Psdz">
					<orgName type="full">Alzheimer&apos;s Association</orgName>
					<orgName type="abbreviated">AA</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000957</idno>
				</funder>
				<funder ref="#_CSMc79M">
					<orgName type="full">Instituto Serrapilheira</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100013275</idno>
				</funder>
				<funder ref="#_27xY3DQ #_4sWs6m5 #_963svGZ #_awuYTks">
					<orgName type="full">Swedish Alzheimer Foundation (Alzheimerfonden</orgName>
				</funder>
				<funder ref="#_QhusRD7">
					<orgName type="full">Colin Adair Charitable Foundation</orgName>
				</funder>
				<funder>
					<orgName type="full">Stiftelsen för Gamla Tjänarinnor</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100010815</idno>
				</funder>
				<funder ref="#_FU4PAM3">
					<orgName type="full">BrightFocus Foundation</orgName>
					<orgName type="abbreviated">BFF</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100006312</idno>
				</funder>
				<funder ref="#_f95jDat">
					<orgName type="full">CAPES</orgName>
				</funder>
				<funder ref="#_jCrgeHw">
					<orgName type="full">Weston Brain Institute</orgName>
					<orgName type="abbreviated">WBI</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100012479</idno>
				</funder>
				<funder ref="#_cxegBqj">
					<orgName type="full">Hjärnfonden</orgName>
				</funder>
				<funder>
					<orgName type="full">Olav Thon Foundation</orgName>
				</funder>
				<funder ref="#_xCrS9dS">
					<orgName type="full">Swedish State Support for Clinical Research</orgName>
				</funder>
				<funder ref="#_sxgxJCN">
					<orgName type="full">Agneta Prytz-Folkes &amp; Gösta Folkes Foundation</orgName>
				</funder>
				<funder ref="#_5jPW9Jc">
					<orgName type="full">Swedish Research Council, Vetenskapsrådet</orgName>
				</funder>
				<funder ref="#_KsQyYU9">
					<orgName type="full">European Union Joint Program-Neurodegenerative Disease Research</orgName>
				</funder>
				<funder ref="#_EqVhEWw #_fJfbdhj">
					<orgName type="full">Fundação de Amparo a pesquisa do Rio Grande do Sul (FAPERGS</orgName>
				</funder>
				<funder ref="#_nrBbcNJ">
					<orgName type="full">Swedish government and the County Councils</orgName>
				</funder>
				<funder ref="#_ayyf6WR">
					<orgName type="full">CIHR-CCNA Canadian Consortium of Neurodegeneration in Aging</orgName>
				</funder>
				<funder ref="#_jmXh6C2">
					<orgName type="full">Swedish Brain Foundation (Hjärnfonden</orgName>
				</funder>
				<funder ref="#_YcqHrwt">
					<orgName type="full">Fonds de Recherche du Québec-Santé (FRQS</orgName>
				</funder>
				<funder ref="#_q8BJ7jk">
					<orgName type="full">UK Dementia Research Institute at UCL</orgName>
				</funder>
				<funder ref="#_yC9TC3f #_t9Xre6q #_RtRXZad #_AQJTVCU #_m7kQUSp #_CsjXe4A">
					<orgName type="full">National Institute on Aging</orgName>
					<orgName type="abbreviated">NIA</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000049</idno>
				</funder>
				<funder>
					<orgName type="full">Bluefield Project</orgName>
				</funder>
				<funder ref="#_BcW8rYN #_dTTvYXh">
					<orgName type="full">European Union</orgName>
				</funder>
				<funder ref="#_cg9HVke #_AQHmESf #_vBMrUNw #_juDpRvP #_Pw9QmNA #_uWmcu7Y #_8xJkvy5 #_a8gEw3Q #_fZJefN8 #_EEKgVju #_4p3YSjm">
					<orgName type="full">unknown</orgName>
				</funder>
				<funder ref="#_DtV26nQ #_rdYqXqr">
					<orgName type="full">National Heart, Lung, and Blood Institute</orgName>
					<orgName type="abbreviated">NHLBI</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000050</idno>
				</funder>
				<funder ref="#_ZcGEvFB #_KpdBch4">
					<orgName type="full">ALF agreement</orgName>
				</funder>
				<funder ref="#_8M5G2tZ #_Ky9qxm3 #_gJbZzAY">
					<orgName type="full">Wallenberg Scholar</orgName>
				</funder>
				<funder ref="#_qDn8VVq">
					<orgName type="full">Alzheimer&apos;s Drug Discovery Foundation</orgName>
					<orgName type="abbreviated">ADDF</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100002565</idno>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">Publisher&apos;s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&apos;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&apos;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/. © The Author(s) 2023</p>
				</availability>
				<date type="published" when="2023-05-29">29 May 2023</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Bruna</forename><surname>Bellaver</surname></persName>
							<idno type="ORCID">0000-0002-2212-3373</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Graduate Program in Biological Sciences-Biochemistry , Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil.</note>
								<orgName type="department">Graduate Program in Biological Sciences-Biochemistry</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Guilherme</forename><surname>Povala</surname></persName>
							<idno type="ORCID">0000-0002-2023-6569</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pamela</forename><forename type="middle">C L</forename><surname>Ferreira</surname></persName>
							<idno type="ORCID">0000-0003-2134-9829</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">João</forename><forename type="middle">Pedro</forename><surname>Ferrari-Souza</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Graduate Program in Biological Sciences-Biochemistry , Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil.</note>
								<orgName type="department">Graduate Program in Biological Sciences-Biochemistry</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Douglas</forename><forename type="middle">T</forename><surname>Leffa</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Firoza</forename><forename type="middle">Z</forename><surname>Lussier</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andréa</forename><forename type="middle">L</forename><surname>Benedet</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Psychiatry and Neurochemistry , The Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden.</note>
								<orgName type="department">Department of Psychiatry and Neurochemistry</orgName>
								<orgName type="institution">The Sahlgrenska Academy at the University of Gothenburg</orgName>
								<address>
									<settlement>Mölndal</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nicholas</forename><forename type="middle">J</forename><surname>Asht</surname></persName>
							<idno type="ORCID">0000-0003-2711-3833</idno>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Psychiatry and Neurochemistry , The Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden.</note>
								<orgName type="department">Department of Psychiatry and Neurochemistry</orgName>
								<orgName type="institution">The Sahlgrenska Academy at the University of Gothenburg</orgName>
								<address>
									<settlement>Mölndal</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Centre for Age-Related Medicine , Stavanger University Hospital , Stavanger , Norway.</note>
								<orgName type="department">Centre for Age-Related Medicine</orgName>
								<orgName type="institution">Stavanger University Hospital</orgName>
								<address>
									<settlement>Stavanger</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> Department of Old Age Psychiatry , Institute of Psychiatry , Psychology and Neuroscience , King&apos;s College London , London , UK.</note>
								<orgName type="department" key="dep1">Department of Old Age Psychiatry</orgName>
								<orgName type="department" key="dep2">Institute of Psychiatry</orgName>
								<orgName type="department" key="dep3">Psychology and Neuroscience</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gallen</forename><surname>Tria-Baltzer</surname></persName>
							<idno type="ORCID">0000-0002-7826-4781</idno>
						</author>
						<author>
							<persName><forename type="first">Hartmuth</forename><forename type="middle">C</forename><surname>Kolb</surname></persName>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>6</label> Neuroscience Biomarkers , Janssen Research and Development , La Jolla , CA , USA.</note>
								<orgName type="department">Neuroscience Biomarkers</orgName>
								<orgName type="institution">Janssen Research and Development</orgName>
								<address>
									<addrLine>La Jolla</addrLine>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cécile</forename><surname>Tissot</surname></persName>
							<idno type="ORCID">0000-0003-2711-3833</idno>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>6</label> Neuroscience Biomarkers , Janssen Research and Development , La Jolla , CA , USA.</note>
								<orgName type="department">Neuroscience Biomarkers</orgName>
								<orgName type="institution">Janssen Research and Development</orgName>
								<address>
									<addrLine>La Jolla</addrLine>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> Translational Neuroimaging Laboratory , McGill University Research Centre for Studies in Aging , Alzheimer&apos;s Disease Research Unit , Douglas Research Institute , Le Centre intégré universitaire de santé et de services sociaux (CIUSSS ) de l&apos;Ouest-de-l&apos;Île-de-Montréal ; Department of Neurology</note>
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="laboratory" key="lab1">Translational Neuroimaging Laboratory</orgName>
								<orgName type="laboratory" key="lab2">Alzheimer&apos;s Disease Research Unit</orgName>
								<orgName type="laboratory" key="lab3">Le Centre intégré universitaire de santé et de services sociaux (CIUSSS</orgName>
								<orgName type="institution" key="instit1">McGill University Research Centre for Studies in Aging</orgName>
								<orgName type="institution" key="instit2">Douglas Research Institute</orgName>
								<orgName type="institution" key="instit3">) de l&apos;Ouest-de-l&apos;Île-de-Montréal</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joseph</forename><surname>Therriault</surname></persName>
							<idno type="ORCID">0000-0002-8546-8256</idno>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> Translational Neuroimaging Laboratory , McGill University Research Centre for Studies in Aging , Alzheimer&apos;s Disease Research Unit , Douglas Research Institute , Le Centre intégré universitaire de santé et de services sociaux (CIUSSS ) de l&apos;Ouest-de-l&apos;Île-de-Montréal ; Department of Neurology</note>
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="laboratory" key="lab1">Translational Neuroimaging Laboratory</orgName>
								<orgName type="laboratory" key="lab2">Alzheimer&apos;s Disease Research Unit</orgName>
								<orgName type="laboratory" key="lab3">Le Centre intégré universitaire de santé et de services sociaux (CIUSSS</orgName>
								<orgName type="institution" key="instit1">McGill University Research Centre for Studies in Aging</orgName>
								<orgName type="institution" key="instit2">Douglas Research Institute</orgName>
								<orgName type="institution" key="instit3">) de l&apos;Ouest-de-l&apos;Île-de-Montréal</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stijn</forename><surname>Servaes</surname></persName>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> Translational Neuroimaging Laboratory , McGill University Research Centre for Studies in Aging , Alzheimer&apos;s Disease Research Unit , Douglas Research Institute , Le Centre intégré universitaire de santé et de services sociaux (CIUSSS ) de l&apos;Ouest-de-l&apos;Île-de-Montréal ; Department of Neurology</note>
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="laboratory" key="lab1">Translational Neuroimaging Laboratory</orgName>
								<orgName type="laboratory" key="lab2">Alzheimer&apos;s Disease Research Unit</orgName>
								<orgName type="laboratory" key="lab3">Le Centre intégré universitaire de santé et de services sociaux (CIUSSS</orgName>
								<orgName type="institution" key="instit1">McGill University Research Centre for Studies in Aging</orgName>
								<orgName type="institution" key="instit2">Douglas Research Institute</orgName>
								<orgName type="institution" key="instit3">) de l&apos;Ouest-de-l&apos;Île-de-Montréal</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jenna</forename><surname>Stevenson</surname></persName>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> Translational Neuroimaging Laboratory , McGill University Research Centre for Studies in Aging , Alzheimer&apos;s Disease Research Unit , Douglas Research Institute , Le Centre intégré universitaire de santé et de services sociaux (CIUSSS ) de l&apos;Ouest-de-l&apos;Île-de-Montréal ; Department of Neurology</note>
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="laboratory" key="lab1">Translational Neuroimaging Laboratory</orgName>
								<orgName type="laboratory" key="lab2">Alzheimer&apos;s Disease Research Unit</orgName>
								<orgName type="laboratory" key="lab3">Le Centre intégré universitaire de santé et de services sociaux (CIUSSS</orgName>
								<orgName type="institution" key="instit1">McGill University Research Centre for Studies in Aging</orgName>
								<orgName type="institution" key="instit2">Douglas Research Institute</orgName>
								<orgName type="institution" key="instit3">) de l&apos;Ouest-de-l&apos;Île-de-Montréal</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nesrine</forename><surname>Rahmouni</surname></persName>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> Translational Neuroimaging Laboratory , McGill University Research Centre for Studies in Aging , Alzheimer&apos;s Disease Research Unit , Douglas Research Institute , Le Centre intégré universitaire de santé et de services sociaux (CIUSSS ) de l&apos;Ouest-de-l&apos;Île-de-Montréal ; Department of Neurology</note>
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="laboratory" key="lab1">Translational Neuroimaging Laboratory</orgName>
								<orgName type="laboratory" key="lab2">Alzheimer&apos;s Disease Research Unit</orgName>
								<orgName type="laboratory" key="lab3">Le Centre intégré universitaire de santé et de services sociaux (CIUSSS</orgName>
								<orgName type="institution" key="instit1">McGill University Research Centre for Studies in Aging</orgName>
								<orgName type="institution" key="instit2">Douglas Research Institute</orgName>
								<orgName type="institution" key="instit3">) de l&apos;Ouest-de-l&apos;Île-de-Montréal</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Oscar</forename><forename type="middle">L</forename><surname>Lopez</surname></persName>
							<idno type="ORCID">0000-0002-8546-8256</idno>
						</author>
						<author>
							<persName><forename type="first">Dana</forename><forename type="middle">L</forename><surname>Tudorascu</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Victor</forename><forename type="middle">L</forename><surname>Villemagne</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Milos</forename><forename type="middle">D</forename><surname>Ikonomovic</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Serge</forename><surname>Gauthier</surname></persName>
							<idno type="ORCID">0000-0003-3930-4354</idno>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> Translational Neuroimaging Laboratory , McGill University Research Centre for Studies in Aging , Alzheimer&apos;s Disease Research Unit , Douglas Research Institute , Le Centre intégré universitaire de santé et de services sociaux (CIUSSS ) de l&apos;Ouest-de-l&apos;Île-de-Montréal ; Department of Neurology</note>
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="laboratory" key="lab1">Translational Neuroimaging Laboratory</orgName>
								<orgName type="laboratory" key="lab2">Alzheimer&apos;s Disease Research Unit</orgName>
								<orgName type="laboratory" key="lab3">Le Centre intégré universitaire de santé et de services sociaux (CIUSSS</orgName>
								<orgName type="institution" key="instit1">McGill University Research Centre for Studies in Aging</orgName>
								<orgName type="institution" key="instit2">Douglas Research Institute</orgName>
								<orgName type="institution" key="instit3">) de l&apos;Ouest-de-l&apos;Île-de-Montréal</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eduardo</forename><forename type="middle">R</forename><surname>Zimmer</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Graduate Program in Biological Sciences-Biochemistry , Universidade Federal do Rio Grande do Sul , Porto Alegre , Brazil.</note>
								<orgName type="department">Graduate Program in Biological Sciences-Biochemistry</orgName>
								<orgName type="institution">Universidade Federal do Rio Grande do Sul</orgName>
								<address>
									<settlement>Porto Alegre</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Henrik</forename><surname>Zetterberg</surname></persName>
							<idno type="ORCID">0000-0003-3930-4354</idno>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Psychiatry and Neurochemistry , The Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden.</note>
								<orgName type="department">Department of Psychiatry and Neurochemistry</orgName>
								<orgName type="institution">The Sahlgrenska Academy at the University of Gothenburg</orgName>
								<address>
									<settlement>Mölndal</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kaj</forename><surname>Blennow</surname></persName>
							<idno type="ORCID">0000-0002-1890-4193</idno>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Psychiatry and Neurochemistry , The Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden.</note>
								<orgName type="department">Department of Psychiatry and Neurochemistry</orgName>
								<orgName type="institution">The Sahlgrenska Academy at the University of Gothenburg</orgName>
								<address>
									<settlement>Mölndal</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Howard</forename><forename type="middle">J</forename><surname>Aizenstein</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">William</forename><forename type="middle">E</forename><surname>Klunk</surname></persName>
							<idno type="ORCID">0000-0001-6580-1202</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Beth</forename><forename type="middle">E</forename><surname>Snitz</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pauline</forename><surname>Maki</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Rebecca</forename><forename type="middle">C</forename><surname>Thurston</surname></persName>
							<idno type="ORCID">0000-0001-6580-1202</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ann</forename><forename type="middle">D</forename><surname>Cohe</surname></persName>
							<idno type="ORCID">0000-0001-9116-1376</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mary</forename><surname>Ganguli</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><forename type="middle">K</forename><surname>Karikari</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Department of Psychiatry and Neurochemistry , The Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden.</note>
								<orgName type="department">Department of Psychiatry and Neurochemistry</orgName>
								<orgName type="institution">The Sahlgrenska Academy at the University of Gothenburg</orgName>
								<address>
									<settlement>Mölndal</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pedro</forename><surname>Rosa-Neto</surname></persName>
							<idno type="ORCID">0000-0001-9116-1376</idno>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> Translational Neuroimaging Laboratory , McGill University Research Centre for Studies in Aging , Alzheimer&apos;s Disease Research Unit , Douglas Research Institute , Le Centre intégré universitaire de santé et de services sociaux (CIUSSS ) de l&apos;Ouest-de-l&apos;Île-de-Montréal ; Department of Neurology</note>
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="laboratory" key="lab1">Translational Neuroimaging Laboratory</orgName>
								<orgName type="laboratory" key="lab2">Alzheimer&apos;s Disease Research Unit</orgName>
								<orgName type="laboratory" key="lab3">Le Centre intégré universitaire de santé et de services sociaux (CIUSSS</orgName>
								<orgName type="institution" key="instit1">McGill University Research Centre for Studies in Aging</orgName>
								<orgName type="institution" key="instit2">Douglas Research Institute</orgName>
								<orgName type="institution" key="instit3">) de l&apos;Ouest-de-l&apos;Île-de-Montréal</orgName>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Tharick</forename><forename type="middle">A</forename><surname>Pascoal</surname></persName>
							<email>pascoalt@upmc.edu</email>
							<idno type="ORCID">0000-0001-9057-8014</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Department of Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA.</note>
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Pittsburgh</orgName>
								<address>
									<settlement>Pittsburgh</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_YAkP876">Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer&apos;s disease</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2023-05-29">29 May 2023</date>
						</imprint>
					</monogr>
					<idno type="MD5">BFFA36599F80E141AD1E1BEA5FF74187</idno>
					<idno type="DOI">10.1038/s41591-023-02380-x</idno>
					<note type="submission">Received: 23 January 2023 Accepted: 1 May 2023</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T10:20+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="16" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="17" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="18" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="19" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="20" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_8AgnEqM"><p xml:id="_T6FVVq6"><s xml:id="_3Mz5BFY">An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pathology and, consequently, clinical deterioration.</s><s xml:id="_D6NNdDs">In vitro evidence suggests that reactive astrocytes unleash Aβ effects in pathological tau phosphorylation.</s><s xml:id="_hGpcNfw">Here, in a biomarker study across three cohorts (n = 1,016), we tested whether astrocyte reactivity modulates the association of Aβ with tau phosphorylation in CU individuals.</s><s xml:id="_hUhjvkP">We found that Aβ was associated with increased plasma phosphorylated tau only in individuals positive for astrocyte reactivity (Ast + ).</s><s xml:id="_NrZ2GRB">Cross-sectional and longitudinal tau-positron emission tomography analyses revealed an AD-like pattern of tau tangle accumulation as a function of Aβ only in CU Ast + individuals.</s><s xml:id="_U3wt2Vt">Our findings suggest astrocyte reactivity as an important upstream event linking Aβ with initial tau pathology, which may have implications for the biological definition of preclinical AD and for selecting CU individuals for clinical trials.</s></p><p xml:id="_rDGXwvT"><s xml:id="_KSgnqFD">Rapid advances in fluid and neuroimaging biomarkers have facilitated the understanding of the dynamic associations between Alzheimer's disease (AD)-related pathophysiological processes in the living human brain.</s><s xml:id="_Ja2RNkS">These biomarker studies suggest that brain accumulation of amyloid-β (Aβ) precedes tau pathology in cognitively unimpaired (CU) individuals <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref> , which is closely related to the development of cognitive symptoms <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref> .</s><s xml:id="_Bv2dWSC">However, the reasons why Aβ pathology is not associated with AD-related progression in some CU individuals is one of the most pressing questions in the field <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref> .</s><s xml:id="_XYFBeKC">In addition to revealing key biological players associated with disease progression, finding predictive markers of early Aβ-related tau pathology would allow for the identification of CU individuals who are more likely to develop AD even before the first signs of pathological tau, facilitating enrollment in early prevention clinical trials <ref type="bibr" target="#b9">10</ref> .</s></p><p xml:id="_PSUXYQu"><s xml:id="_ttQr78F">The fact that Aβ leads to tau pathology in some individuals, but not in others, suggests the presence of other biological processes capable of triggering the deleterious effects of Aβ in the early disease stages.</s><s xml:id="_Y5ck27a">Postmortem studies show that astrocyte reactivity is a Article <ref type="url" target="https://doi.org/10.1038/s41591-023-02380-x">https://doi.org/10.1038/s41591-023-02380-x</ref></s><s xml:id="_eXaXdem">Aβ burden and plasma p-tau181 in CU Ast + (β = 0.34, t = 5.37, P &lt; 0.0001; Fig. <ref type="figure" target="#fig_0">1b</ref> and Extended Data Table <ref type="table" target="#tab_0">1</ref>) but not in CU Ast -(β = 0.04, t = 1.06,</s><s xml:id="_MBAArms">P = 0.29; Fig. <ref type="figure" target="#fig_0">1b</ref>) individuals.</s><s xml:id="_gSNvCFE">A significant interaction between Aβ burden and astrocyte reactivity status on plasma p-tau181 (β = 0.31, t = 4.62, P &lt; 0.0001; Fig. <ref type="figure" target="#fig_0">1b</ref>) further supported that the presence of astrocyte reactivity was key to determining Aβ effects on tau phosphorylation.</s><s xml:id="_CdePBhz">These results were replicated using different cutoff values to determine reactive astrocyte positivity (Extended Data Table <ref type="table">2</ref>).</s><s xml:id="_RAwrtvE">In addition, linear regression using only continuous values for Aβ, p-tau181 and GFAP levels confirmed that these results were not driven by biomarker thresholds (β = 0.10, t = 3.22, P = 0.0013; Fig. <ref type="figure" target="#fig_0">1c</ref>).</s><s xml:id="_txCyfz2">Cohen's d analysis revealed that the presence of both Aβ + and Ast + has a large magnitude of effect on tau phosphorylation (Cohen's d = 0.80), whereas Aβ + in the absence of Ast + presented a negligible effect size (Fig. <ref type="figure" target="#fig_0">1d</ref>).</s><s xml:id="_ddRbJBE">Voxel-wise analysis confirmed that Aβ levels associated with plasma p-tau181 only in the presence of astrocyte reactivity in some brain regions previously shown to present early Aβ pathology in PET studies, including the posterior cingulate, precuneus and insula <ref type="bibr" target="#b24">25</ref> (Fig. <ref type="figure" target="#fig_0">1e</ref>).</s></p><p xml:id="_gvKQCfr"><s xml:id="_WPuu4Qt">Consistently, the stratified analysis within cohorts showed similar results.</s><s xml:id="_PmAA48E">In the three enrollment sites, plasma p-tau181 levels increased as a function of Aβ burden only in CU Ast + (Pittsburgh: β = -0.35,</s><s xml:id="_ZE4VfmT">t = 3.10, P = 0.003 (Fig. <ref type="figure" target="#fig_0">1f</ref>); MYHAT: β = -0.20,</s><s xml:id="_VRYXAjn">t = 2.26, P = 0.026 (Fig. <ref type="figure" target="#fig_0">1h</ref>) and TRIAD: β = 0.57, t = 4.36, P &lt; 0.0001 (Fig. <ref type="figure" target="#fig_0">1j</ref>)).</s><s xml:id="_xyx4J6g">A steeper increase in plasma p-tau181 was observed in the research cohorts (TRIAD and Pittsburgh) compared to the population-based cohort (MYHAT).</s><s xml:id="_BUwRqn4">Similarly, we observed a significant interaction between Aβ burden and astrocyte reactivity status on plasma p-tau181 levels in the Pittsburgh (β = -0.29,</s><s xml:id="_fCKJuzr">t = 2.30, P = 0.022; Fig. <ref type="figure" target="#fig_0">1g</ref>), MYHAT (β = -0.19,</s><s xml:id="_dr3BQqY">t = 2.07, P = 0.039; Fig. <ref type="figure" target="#fig_0">1i</ref>) and TRIAD (β = 0.46, t = 2.92, P = 0.004; Fig. <ref type="figure" target="#fig_0">1k</ref>) cohorts.</s><s xml:id="_KZ8xFmh">In a subset of participants from the Pittsburgh and MYHAT cohorts with available Aβ-PET (n = 150), we also found increased plasma p-tau181 as a function of Aβ-PET only in Ast + (Extended Data Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_CJbFXda">No significant effect of apolipoprotein ε4 (APOE ε4) status was observed in the aforementioned associations (Extended Data Table <ref type="table">3</ref>).</s></p><p xml:id="_GDW4RVh"><s xml:id="_gPV3EVD">We also explored the impact of Ast + in the associations of Aβ burden with plasma p-tau231 (available for Pittsburgh and TRIAD cohorts, n = 502) and p-tau217 (available for the TRIAD cohort, n = 136) levels in subsets of individuals that had these markers available.</s><s xml:id="_mqs4WqR">Plasma p-tau231 increased as a function of Aβ only in CU Ast + individuals (Fig. <ref type="figure" target="#fig_0">1l</ref>).</s><s xml:id="_UvupJSx">Additionally, we found a significant association between Aβ and plasma p-tau231 in CU Ast + (β = 0.36, t = 4.62, P &lt; 0.0001; Fig. <ref type="figure" target="#fig_0">1m</ref> and Extended Data Table <ref type="table">3</ref>) but not in CU Ast -individuals (β = 0.10, t = 1.87,</s><s xml:id="_zs8cnQu">P = 0.06).</s><s xml:id="_WKbpkEV">We also observed a significant interaction between Aβ and astrocyte reactivity status on plasma p-tau231 (β = 0.26, t = 2.84, P = 0.004; Fig. <ref type="figure" target="#fig_0">1m</ref>).</s><s xml:id="_kHWJDhv">common neuropathological finding in CU individuals and, like cortical Aβ plaques, one of the earliest abnormalities in AD <ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref> .</s><s xml:id="_tQQ7sqW">Experimental literature suggests that astrocyte reactivity is critical for triggering Aβ-induced tau phosphorylation <ref type="bibr" target="#b15">16</ref> and that the attenuation of astrocyte reactivity mitigates tau pathology <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b17">18</ref> .</s><s xml:id="_TMb9tvV">Additionally, glial fibrillary acidic protein (GFAP)-positive astrocytes can internalize tau and may contribute to its propagation <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref> .</s><s xml:id="_vdFVRWs">Altogether, these experimental results support a close link between Aβ, astrocyte reactivity and tau.</s></p><p xml:id="_2VFmjVP"><s xml:id="_RBEjJtm">Clinical studies support that plasma measures of GFAP correlate with its CSF levels and are increased in CU individuals with AD pathophysiology, representing a robust proxy of astrocyte reactivity in the brains of these individuals <ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref> .</s><s xml:id="_uSajpaH">Based on this previous literature, we designed a multisite biomarker study including three cohorts to test the hypothesis that the presence of astrocyte reactivity biomarker abnormality is a key element in determining the association of Aβ burden with early tau phosphorylation and aggregation biomarkers in preclinical AD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_6ADQPgb">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ecM24ME">Participants</head><p xml:id="_utSZX9S"><s xml:id="_eAGnN6F">We investigated 1,016 CU individuals (mean age = 69.6 ± 8.9, clinical dementia rating (CDR) = 0) from two research (Translational Biomarkers in Aging and Dementia (TRIAD), McGill University, Canada and Pittsburgh, University of Pittsburgh, USA) and one population-based (Monongahela-Youghiogheny Healthy Aging Team (MYHAT), Pittsburgh, USA) cohorts with in vivo biomarkers.</s><s xml:id="_vjktQXu">Individuals were classified as negative (Ast -) or positive (Ast + ) for astrocyte reactivity based on their plasma GFAP levels.</s><s xml:id="_gg9nMdU">Demographic and clinical characteristics of participants are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s><s xml:id="_awR2ZEd">Overall, participants classified as Aβ + /Ast + presented increased plasma phosphorylated tau (p-tau)181, p-tau231 and p-tau217 compared to other groups.</s><s xml:id="_ppNPbjG">No differences in Aβ levels were observed between CU Aβ + /Ast -and Aβ + /Ast + in any cohort.</s><s xml:id="_T5cMVTk">Demographic characteristics of individuals segregated by cohort are presented in Supplementary Tables <ref type="table" target="#tab_0">1</ref><ref type="table">2</ref><ref type="table">3</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JDKNXZd">Astrocyte reactivity affects Aβ-dependent tau phosphorylation</head><p xml:id="_JBE5qKM"><s xml:id="_gFQtKxE">We z scored biomarker levels inside each cohort and applied a robust linear regression to model the trajectory of plasma p-tau181, the only p-tau biomarker available in all cohorts, as a function of Aβ burden (plasma or positron emission tomography (PET)) in CU individuals classified as Ast - (n = 743) or Ast + (n = 273).</s><s xml:id="_WDE5DbJ">Notably, we observed that plasma p-tau181 levels increased as a function of Aβ only in CU Ast + individuals (Fig. <ref type="figure" target="#fig_0">1a</ref>).</s><s xml:id="_bGabckh">Similarly, linear regression showed a significant association between Cohen's d analysis suggests that the presence of both Aβ + and Ast + also had a strong effect on the levels of plasma p-tau231 (Cohen's d = 0.91), whereas pathologies independently did not have a significant effect (Fig. <ref type="figure" target="#fig_0">1n</ref>).</s><s xml:id="_GjgTZH7">Similarly, plasma p-tau217 presented a steeper increase as a function of Aβ burden in Ast + compared to Ast -(Fig.</s><s xml:id="_g2dT2Zx"><ref type="figure" target="#fig_0">1o</ref> and Extended Data Table <ref type="table">4</ref>).</s><s xml:id="_gchZyUM">An association between Aβ burden and plasma p-tau217 was observed in Ast -(β = 0.21, t = 3.74, P = 0.0004; Fig. <ref type="figure" target="#fig_0">1p</ref>), but with a much larger magnitude in Ast + (β = 0.76, t = 5.91, P &lt; 0.0001; Fig. <ref type="figure" target="#fig_0">1p</ref>).</s><s xml:id="_86B6W2U">The stronger association in CU Ast + individuals was further evidenced by a significant interaction between Aβ burden and astrocyte reactivity status on plasma p-tau217 (β = 0.53, t = 3.74, P = 0.0003; Fig. <ref type="figure" target="#fig_0">1p</ref>).</s><s xml:id="_YwVEEfs">The presence of both Aβ + and Ast + had the largest effect size on plasma p-tau217 increase (Cohen's d = 1.41;</s><s xml:id="_PM7HY2c">Fig. <ref type="figure" target="#fig_0">1q</ref>) compared to p-tau181 and p-tau231.</s><s xml:id="_DK6b89G">Notably, the presence of astrocyte reactivity did not impact the association between Aβ burden and neurofilament light levels in any of the three cohorts (Supplementary Table <ref type="table">4</ref>), supporting that astrocyte reactivity unleashes Aβ effects on early tau pathology but not on neurodegeneration.</s><s xml:id="_Zz7fJUS">We did not observe a significant effect of microglial activation abnormality on the association between Aβ and p-tau in a subset of individuals with available CSF soluble triggering a, Robust linear regressions show that plasma p-tau181 increases as a function of Aβ burden only in the presence of astrocyte reactivity (Ast + ) in all cohorts together (n = 1,016).</s><s xml:id="_dU3VQBC">b, Linear regressions adjusted for age and sex revealed an interaction between Aβ burden and astrocyte reactivity status on p-tau181 levels in all cohorts (n = 1,016).</s><s xml:id="_4PvnxbZ">Shaded areas represent 95% confidence intervals of the regression lines.</s><s xml:id="_Z2U59Qf">c, Continuous association between Aβ pathology, plasma p-tau181 and plasma GFAP adjusted for age and sex (n = 1,016).</s><s xml:id="_NbQwGME">d, Cohen's d analysis accounting for age and sex shows the effect sizes of Aβ and astrocyte reactivity status on plasma p-tau181 (n = 1,016).</s><s xml:id="_6hQBWaA">The error bars represent the 95% confidence interval.</s><s xml:id="_wnwm9R5">e, Voxel-wise regressions, corrected for multiple comparisons, show that Aβ-PET is associated with plasma p-tau181 only in CU Ast + in typical AD regions (TRIAD cohort, n = 147).</s><s xml:id="_b6RR7Pv">f-k, Robust locally weighted and linear regressions adjusted for age and sex show that plasma p-tau181 increases as a function of Aβ burden only in Ast + individuals and with a significant interaction between Aβ and astrocyte reactivity status on p-tau181 levels in (f,g) Pittsburgh (n = 355), (h,i) MYHAT (n = 514) and (j,k) TRIAD (n = 147) cohorts.</s><s xml:id="_JdaKcqJ">Shaded areas represent 95% confidence intervals of the regression lines.</s><s xml:id="_tTeEhxg">l,m, Robust locally weighted and linear regressions adjusted for age and sex show that (l) plasma p-tau231 increases as a function of Aβ burden only in Ast+ individuals and with (m) a significant interaction between Aβ burden and astrocyte reactivity status on p-tau231 (n = 502).</s><s xml:id="_nEHdHe3">n, Cohen's d analysis accounting for age and sex shows the effect sizes of Aβ and astrocyte reactivity status on plasma p-tau231 (n = 502).</s><s xml:id="_ehKhfbB">The error bars represent the 95% confidence intervals.</s><s xml:id="_nE9RMcX">o,p, Robust locally weighted and linear regressions adjusted for age and sex show that (o) plasma p-tau217 increases as a function of Aβ burden only in Ast+ individuals and with (p) a significant interaction between Aβ burden and astrocyte reactivity status on p-tau217 (n = 136).</s><s xml:id="_d6egmTk">Shaded areas represent 95% confidence intervals of the regression lines.</s><s xml:id="_bHgKZpS">For illustrative purposes only, two individuals with high plasma p-tau181 and p-tau217 concentrations were not shown in k and p, but they were fully included in the statistical analyses.</s><s xml:id="_YGcu2Jq">q, Cohen's d analysis accounting for age and sex shows the effect sizes of Aβ and astrocyte reactivity status on plasma p-tau217 (n = 136).</s><s xml:id="_aM9EBr7">The error bars represent the 95% confidence intervals.</s><s xml:id="_j7emQkv">r, β estimates with respective 95% confidence interval of linear regressions showing the effect of sex on the associations of Aβ with plasma p-tau epitopes in Ast -and Ast + (n = 1,016).</s><s xml:id="_yMhqSXY">Green dots represent men and orange dots women.</s><s xml:id="_4CwmztG">Solid dots represent Ast + individuals.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_qkPmWDV">Article</head><p xml:id="_w9YjGuF"><s xml:id="_SDk6rhA"><ref type="url" target="https://doi.org/10.1038/s41591-023-02380-x">https://doi.org/10.1038/s41591-023-02380-x</ref></s><s xml:id="_j5caJaH">receptor expressed on myeloid cells 2 (sTREM2) in the TRIAD cohort, whereas the effect of astrocyte reactivity remained present in this subgroup (n = 67; Extended Data Table <ref type="table">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RfecEhq">Sex affects the association of astrocyte reactivity, Aβ and tau</head><p xml:id="_3ZSmezJ"><s xml:id="_7gJ6fCh">We further investigated whether the effects of astrocyte reactivity on the association between Aβ and p-tau differ between men and women.</s><s xml:id="_zensvjr">In Ast + , men presented a higher magnitude of association between Aβ and plasma p-tau181 (men-β = 0.72, P &lt; 0.0001; women-β = 0.27, P = 0.00011; Fig. <ref type="figure" target="#fig_0">1r</ref>; Extended Data Fig. <ref type="figure" target="#fig_1">2</ref> and Supplementary Fig. <ref type="figure" target="#fig_0">1</ref>), p-tau231 (men-β = 0.59, P = 0.0013; women-β = 0.33, P = 0.0003; Fig. <ref type="figure" target="#fig_0">1r</ref> and Extended Data Fig. <ref type="figure" target="#fig_1">2</ref>) and p-tau217 (men-β = 1.23,</s><s xml:id="_ek3RMnz">P = 0.0009; women-β = 0.54, P &lt; 0.0001; Fig. <ref type="figure" target="#fig_0">1r</ref> and Extended Data Fig. <ref type="figure" target="#fig_1">2</ref>) compared to women.</s><s xml:id="_tfPpZVW">A significant interaction between Aβ and sex on plasma p-tau181 (β = 0.47, P = 0.005; Extended Data Fig. <ref type="figure" target="#fig_1">2</ref>) and p-tau217 (β = 1.01,</s><s xml:id="_XRJYGYY">P = 0.002; Extended Data Fig. <ref type="figure" target="#fig_1">2</ref>), but not p-tau231 (β = 0.26, P = 0.27; Extended Data Fig. <ref type="figure" target="#fig_1">2</ref>), was observed in the Ast + group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_V65mnkz">Astrocyte reactivity impacts Aβ and tau tangle association</head><p xml:id="_VGSrYR5"><s xml:id="_D78QrUe">We used tau-PET imaging available in the TRIAD cohort to determine the topographic localization of p-tau protein aggregates in the form of tangles (n = 147).</s><s xml:id="_zZaXGdc">Tau-PET deposition occurred as a function of Aβ-PET only in CU Ast + and in regions expected to present the earliest tau deposition (Fig. <ref type="figure" target="#fig_1">2a</ref>), affecting 100% and 62% of the extension of the Braak I and II regions, respectively (Fig. <ref type="figure" target="#fig_1">2b</ref>).</s><s xml:id="_hUytz62">As expected, in later Braak regions tau-PET, uptake did not increase as a function of Aβ in either group (Fig. <ref type="figure" target="#fig_1">2b</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vZYQuZP">Astrocyte reactivity affects longitudinal tau tangle accumulation</head><p xml:id="_HcJvHT9"><s xml:id="_N2wVkeZ">We investigated the link of baseline Aβ and astrocyte reactivity status with future tau-PET burden (n = 71; mean follow-up = 2.3 years; Supplementary Table <ref type="table">5</ref>).</s><s xml:id="_s74U4kW">We observed that the annual rate of tau-PET accumulation was higher in CU Ast + (Fig. <ref type="figure">3a</ref>) and was predicted by baseline Aβ burden only in CU Ast + (Fig. <ref type="figure">3b</ref>).</s><s xml:id="_xTn5yMw">Interestingly, while the baseline association was confined to the mesial temporal cortex, the longitudinal tau-PET accumulation as a function of Aβ/Ast presented initial tau spread over the neocortex in Braak III-IV regions (32.5% of Braak III and 30% of Braak IV areas; Fig. <ref type="figure">3c</ref>), further supporting the notion that these individuals are following a tau accumulation pathway consistent with AD progression <ref type="bibr" target="#b25">26</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_497Z4KW">Discussion</head><p xml:id="_uteRN3k"><s xml:id="_7wh3MBs">In summary, we provide biomarker evidence across multiple cohorts that shows that increased astrocyte reactivity, as indicated by elevated plasma GFAP, plays a role in the association of Aβ with early tau phosphorylation in preclinical AD.</s></p><p xml:id="_sjWwSNQ"><s xml:id="_VXTZYNp">The fact that the presence of abnormal astrocyte reactivity determined Aβ-triggered tau pathology in CU individuals may prove to favor the inclusion of astrocyte reactivity biomarkers in the biomarker modeling <ref type="bibr" target="#b0">1</ref> and biological definitions <ref type="bibr" target="#b26">27</ref> of AD.</s><s xml:id="_abaAsA4">Our findings support previous biomarker studies in suggesting that plasma p-tau levels rise in response to early Aβ in preclinical AD <ref type="bibr" target="#b2">3</ref> but also add that this occurs mainly in the concomitant presence of astrocyte reactivity biomarker abnormality.</s><s xml:id="_pkJSuxN">These results suggest that astrocyte reactivity abnormality could be placed as an early upstream event, likely before tau pathology, in the hypothetical biomarker models of AD progression <ref type="bibr" target="#b27">28</ref> .</s><s xml:id="_KKKuaRf">Furthermore, we can argue that an Aβ/Ast/p-tau biomarker scheme could provide a more granular early classification for preclinical AD.</s><s xml:id="_aQrCYx7">Specifically, CU classified as Aβ + and Ast + would be more likely to progress to tau positivity, which is closely related to the development of neurodegeneration and cognitive decline <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30</ref> .</s><s xml:id="_VbY2ENh">Further studies measuring Aβ, tau and GFAP biomarkers at multiple time points with long follow-up durations are needed to confirm the temporal order of appearance of each biomarker abnormality and to determine other possible factors associated with early astrocyte reactivity in preclinical AD.</s></p><p xml:id="_YrdrRgP"><s xml:id="_vZKGVmq">Our results may have implications for clinical trials.</s><s xml:id="_WZSBNH4">As clinical trials have increasingly focused on individuals in the earliest preclinical phases of AD, our results highlight that the selection of Aβ + /Ast + CU Although our sensitivity analysis supported plasma GFAP levels 2 s.d.</s><s xml:id="_c2x3Vpn">above the mean of CU devoid of detectable Aβ as a robust cutoff to enhance Aβ and p-tau association, a cutoff validation using antemortem blood samples associated with postmortem GFAP characterization is desirable.</s><s xml:id="_EjC9n9A">In addition, experimental literature suggests as a possible mechanism underlying our findings that Aβ-mediated astrocyte signaling (for example, through cytokines, caspases and reactive oxygen species) induces tau pathology <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b28">29</ref> , which is corroborated by studies showing that the suppression of this signaling is able to halt tau phosphorylation <ref type="bibr" target="#b16">17</ref> .</s><s xml:id="_zeax23s">Thus, we can speculate that a combination of drugs targeting Aβ and reactive astrocyte mediators may potentiate the prevention of early tau pathology in trials conducted in preclinical AD individuals.</s><s xml:id="_pREdWcD">We found that the effect of astrocyte reactivity on the association between Aβ and tau phosphorylation was greater in CU men than women.</s><s xml:id="_vgC5ju9">Previous studies have shown increased tau biomarkers in women compared to men; however, whether this is driven by Aβ or other sex-specific factors remains unclear <ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref> .</s><s xml:id="_CwXHkmn">Therefore, our results showing that astrocyte reactivity had a greater impact on the association of Aβ with tau in men does not contradict the above-mentioned previous studies.</s><s xml:id="_qCEUcaq">In fact, our findings might be reflected in the recent outcomes of anti-Aβ therapies, which might be modifying this Aβastrocyte-tau pathway, showing a higher magnitude of effect in men than women <ref type="bibr" target="#b33">34</ref> .</s></p><p xml:id="_JV8ZHAW"><s xml:id="_6weDZ9G">The strengths of our study include a large sample size for the main analysis and the use of well-characterized research and population-based cohorts.</s><s xml:id="_cgYYk3w">Limitations include the fact that the analysis using longitudinal tau-PET had a relatively small sample size; thus, replication of this finding is highly desirable.</s><s xml:id="_Sj2jNj4">As biomarkers are naturally continuous, dichotomizing cutoffs are invariably subjected to conceptual and analytical idiosyncrasies and may change depending on the method used.</s><s xml:id="_x7EvTeC">Finally, although our cohort represents significant socioeconomic diversity, the main limitation is that our cohorts are composed mainly of White participants, which limits the generalizability of our findings to a more diverse world population.</s></p><p xml:id="_v8J8anm"><s xml:id="_Ry5HeGm">In conclusion, our findings suggest that detecting astrocyte reactivity biomarker abnormality is critical to predict whether CU Aβ-positive individuals will develop tau pathology and, consequently, clinical symptoms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_DzwkZss">Online content</head><p xml:id="_qQ7daeC"><s xml:id="_vxbAbzx">Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <ref type="url" target="https://doi.org/10.1038/s41591-023-02380-x">https://doi.org/10.1038/s41591-023-02380-x</ref>. were assessed with linear regressions accounting for age and sex.</s><s xml:id="_uAevCjA">An interaction term between Aβ burden × astrocyte reactivity status/or plasma GFAP as a continuous variable was also added to each model.</s><s xml:id="_BKGKcjM">For analyses including all cohorts, we included cohort as a covariate to adjust for variability in differences between cohorts.</s><s xml:id="_7YtfuD6">For all linear regression analyses, z scores were centered on the mean within each cohort, and z scores for plasma Aβ ratio were inverted to pool plasma Aβ and Aβ-PET levels together.</s><s xml:id="_7Paz89B">To determine sex effects in our findings, we included an interaction term between Aβ burden × sex on plasma p-tau considering individuals that are Ast -and Ast + .</s><s xml:id="_kq7uQYh">Voxel-wise associations between biomarkers were tested using linear regressions accounting for age and sex, and adjusted for multiple comparisons using a random field theory threshold of P &lt; 0.001 (ref.</s><s xml:id="_TFyQeQA">51).</s><s xml:id="_4AcN8xM">We evaluated the percentage of abnormality across PET Braak-like stages by dividing the total number of voxels by the number of significant voxels after multiple comparison corrections.</s><s xml:id="_6yxzc82">We measured the annual rate of progression in ( 18 F)MK-6240 uptake as the difference between follow-up and baseline uptakes divided by the time between scans.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>fFig. 1 |</head><label>1</label><figDesc><div><p xml:id="_rEm4YMU"><s xml:id="_DjnPWbd">Fig.1| Astrocyte reactivity influences Aβ-dependent tau phosphorylation.</s><s xml:id="_5H4pbCQ">a, Robust linear regressions show that plasma p-tau181 increases as a function of Aβ burden only in the presence of astrocyte reactivity (Ast + ) in all cohorts together (n = 1,016).</s><s xml:id="_P4JVvYr">b, Linear regressions adjusted for age and sex revealed an interaction between Aβ burden and astrocyte reactivity status on p-tau181 levels in all cohorts (n = 1,016).</s><s xml:id="_4aReH2j">Shaded areas represent 95% confidence intervals of the regression lines.</s><s xml:id="_dYFy3Hn">c, Continuous association between Aβ pathology, plasma p-tau181 and plasma GFAP adjusted for age and sex (n = 1,016).</s><s xml:id="_ETzxVsn">d, Cohen's d analysis accounting for age and sex shows the effect sizes of Aβ and astrocyte reactivity status on plasma p-tau181 (n = 1,016).</s><s xml:id="_8guc6K9">The error bars represent the 95% confidence interval.</s><s xml:id="_nBNwZbD">e, Voxel-wise regressions, corrected for multiple comparisons, show that Aβ-PET is associated with plasma p-tau181 only in CU Ast + in typical AD regions (TRIAD cohort, n = 147).</s><s xml:id="_JUb2dMh">f-k, Robust locally weighted and linear regressions adjusted for age and sex show that plasma p-tau181 increases as a function of Aβ burden only in Ast + individuals and with a significant interaction between Aβ and astrocyte reactivity status on p-tau181 levels in (f,g) Pittsburgh (n = 355), (h,i) MYHAT (n = 514) and (j,k) TRIAD (n = 147) cohorts.</s><s xml:id="_8GNpxtR">Shaded areas represent 95% confidence intervals of the regression lines.</s><s xml:id="_wabKnbA">l,m, Robust locally weighted and linear regressions adjusted for age and sex</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 |</head><label>2</label><figDesc><div><p xml:id="_2bUKHbG"><s xml:id="_dVsnksa">Fig. 2 | Astrocyte reactivity impacts the association of Aβ with tau-PET deposition.</s><s xml:id="_yHSbPNb">a, Voxel-wise regression analysis showing the association between Aβ-PET and tau-PET in individuals classified as negative (Ast -) or positive (Ast + ) for astrocyte reactivity (n = 147).</s><s xml:id="_ggFPCym">b, Percentage of the extent of the brain region</s></p></div></figDesc><graphic coords="4,41.43,77.18,169.53,195.61" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>2 6Fig. 3 |</head><label>23</label><figDesc><div><p xml:id="_GTaAgcP"><s xml:id="_X8f3Rer">Fig. 3 | Astrocyte reactivity potentiates longitudinal tau tangle accumulation.</s><s xml:id="_s9bDVYR">a, Longitudinal tau-PET annual rate of change according to astrocyte reactivity status (n = 71).</s><s xml:id="_vXcgxS7">b, Association between tau-PET annual rate of change and baseline Aβ-PET according to astrocyte reactivity status.</s><s xml:id="_jRUy6ZH">c, Percentage of voxels with significant association (after RFT correction) between tau-PET annual rate of change and baseline Aβ-PET in each Braak region.</s><s xml:id="_hHcK5EY">Associations were tested using voxel-wise linear regression models corrected for RFT multiple comparison and adjusted by age and sex.</s></p></div></figDesc><graphic coords="5,36.22,83.93,176.94,248.51" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="12,89.83,105.69,454.32,355.68" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="16,41.09,82.73,518.76,311.76" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 | Demographics and key characteristics of participants Characteristics Aβ -/Ast -(n = 557) Aβ -/Ast + (n = 165) Aβ + /Ast -(n = 186) Aβ + /Ast + (n = 108)</head><label>1</label><figDesc><div><p xml:id="_thHcXPS"><s xml:id="_aduRm3R">Missing APOE ε4: 140 Aβ -/Ast -, 43 A -/Ast + , 45 Aβ + /Ast -and 17 Aβ + /Ast + .</s><s xml:id="_8Jayf2E">Missing neurofilament light: 2 Aβ -/Ast -, 2 Aβ -/Ast + and 1 Aβ + /Ast -.</s><s xml:id="_7tMCkZ4">Plasma p-tau231 is available for a subset of participants from TRIAD and Pittsburgh cohorts.</s><s xml:id="_RCHWzjU">Plasma p-tau217 is available for a subset of participants from the TRIAD cohort.</s><s xml:id="_UDYqU7U">a Different from Aβ -/Ast -. b Different from Aβ -/Ast + .</s><s xml:id="_sUBGVTZ">c Different from Aβ + /Ast -.</s></p></div></figDesc><table><row><cell>Age, mean (s.d.)</cell><cell>68.2 (8.6)</cell><cell>72.1 (8.2) a</cell><cell>68.6 (7.6) b</cell><cell>74.7 (10.6) a,c</cell></row><row><cell>Sex, n (% female)</cell><cell>367 (65.9)</cell><cell>137 (83.0) a</cell><cell>122 (65.6) b</cell><cell>79 (73.1)</cell></row><row><cell>MMSE/MoCA, mean (s.d.)</cell><cell>28.1 (3.3)/27.5 (1.8)</cell><cell>28.1 (3.2)/28.1 (1.7)</cell><cell>27.8 (3.2)/26.7 (4.1) b</cell><cell>27.1 (6.1)/27.2 (1.4)</cell></row><row><cell>APOE ε4 (% of carriers)</cell><cell>89 (16.0)</cell><cell>25 (15.2)</cell><cell>33 (17.7)</cell><cell>25 (23.1)</cell></row><row><cell>Education, years (s.d.)</cell><cell>15.0 (2.7)</cell><cell>15.2 (3.1)</cell><cell>14.8 (2.7)</cell><cell>15.0 (2.8)</cell></row><row><cell>Aβ burden (z score, s.d.)</cell><cell>-0.52 (0.65)</cell><cell>-0.40 (0.57)</cell><cell>1.17 (0.63) a,b</cell><cell>1.25 (0.69) a,b</cell></row><row><cell>Plasma GFAP (z score, s.d.)</cell><cell>-0.50 (0.51)</cell><cell>1.20 (0.75) a</cell><cell>-0.42 (0.52) b</cell><cell>1.48 (0.88) a,b,c</cell></row><row><cell>Plasma p-tau181 (z score, s.d.)</cell><cell>-0.12 (0.90)</cell><cell>0.10 (0.82) a</cell><cell>-0.14 (0.97)</cell><cell>0.77 (1.89) a,b,c</cell></row><row><cell>Plasma p-tau231 (z score, s.d.)</cell><cell>-0.03 (1.00)</cell><cell>-0.12 (0.82)</cell><cell>-0.04 (0.86)</cell><cell>0.55 (1.26) a,b,c</cell></row><row><cell>Plasma p-tau217 (z score, s.d.)</cell><cell>-0.27 (0.38)</cell><cell>-0.24 (0.38)</cell><cell>0.17 (0.49)</cell><cell>1.12 (1.99) a,b,c</cell></row><row><cell>Plasma neurofilament light (z</cell><cell>-0.24 (0.62)</cell><cell>0.42 (0.99) a</cell><cell>-0.13 (1.22) b</cell><cell>0.80 (1.47) a,b,c</cell></row><row><cell>score, s.d.)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note xml:id="_rNb4GWK"><p><s xml:id="_jgxXnY3">Article https://doi.org/10.1038/s41591-023-02380-x</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_2gbwpxJ">Acknowledgements</head><p xml:id="_UuAJr5S"><s xml:id="_WyFqhCQ">We thank all TRIAD, MYHAT and Pittsburgh studies personnel for their effort and participants for their time, data and specimens.</s><s xml:id="_4r7jshg">We would like to thank the following funding agencies that supported this work: <rs type="funder">NIH</rs>, <rs type="funder">National Institute of Aging</rs> (grants <rs type="grantNumber">R01AG075336</rs> and <rs type="grantNumber">R01AG073267</rs> to T.A.P.; <rs type="grantNumber">RF1AG053504</rs> and <rs type="grantNumber">R01AG053504</rs> to R.C.T.; <rs type="grantNumber">RF1AG053504</rs> to P.M.; <rs type="grantNumber">R01AG052528</rs>, <rs type="grantNumber">P01AG14449</rs> and <rs type="grantNumber">P01AG025204</rs> to M.D.I.); <rs type="funder">NIH</rs>, <rs type="funder">National Heart Lung and Blood Institute</rs> (grants <rs type="grantNumber">R01HL105647</rs> and <rs type="grantNumber">K24HL123565</rs> to R.C.T.); <rs type="funder">Alzheimer's Association</rs> (grants <rs type="grantNumber">AARFD-22-974627</rs> to B.B.; <rs type="grantNumber">AACSF-20-648075</rs> to T.A.P.; <rs type="grantNumber">AARF-21-850325</rs> to T.K.K.; <rs type="grantNumber">AARFD-22-923814</rs> to P.C.L.F.; <rs type="grantNumber">AARGD-21-850670</rs> to E.R.Z.; <rs type="grantNumber">ADSF-21-831376-C</rs>, <rs type="grantNumber">ADSF-21-831381-C</rs> and <rs type="grantNumber">ADSF-21-831377-C</rs> to H.Z.); <rs type="funder">CAPES</rs> (grant <rs type="grantNumber">88887</rs>.<rs type="grantNumber">336490/2019-00</rs> to B.B.); <rs type="funder">CNPq</rs> (grant <rs type="grantNumber">200691/2021-0</rs> to J.P.F.-S); <rs type="funder">Fonds de Recherche du Québec-Santé (FRQS</rs>; <rs type="funder">Chercheur Boursier</rs>, grant <rs type="grantNumber">2020-VICO-279314</rs> to P.R.-N.);</s><s xml:id="_PfH5u6c"><rs type="funder">CIHR-CCNA Canadian Consortium of Neurodegeneration in Aging</rs> (grants <rs type="grantNumber">MOP-11-51-31</rs>; <rs type="grantNumber">RFN 152985</rs>, <rs type="grantNumber">159815</rs>, <rs type="grantNumber">162303</rs> to P.R.-N.);</s><s xml:id="_x6a5MhF"><rs type="funder">Weston Brain Institute</rs> (grants <rs type="grantNumber">8400707</rs>, <rs type="grantNumber">8401154</rs> and <rs type="grantNumber">8401103</rs> to P.R.-N.);</s><s xml:id="_pT98sND"><rs type="funder">Colin Adair Charitable Foundation</rs> (grant to P.R.-N.);</s><s xml:id="_BRWdvpA"><rs type="funder">Swedish Research Council, Vetenskapsrådet</rs> (grant <rs type="grantNumber">2021-03244</rs> to T.K.K.); <rs type="funder">Wallenberg Scholar</rs> (grant <rs type="grantNumber">2022-01018</rs> to H.Z.; <rs type="grantNumber">2017-00915</rs> and <rs type="grantNumber">2022-00732</rs> to K.B.); <rs type="funder">BrightFocus Foundation</rs> (grant <rs type="grantNumber">A2020812F</rs> to T.K.K.); <rs type="funder">Swedish Alzheimer Foundation (Alzheimerfonden</rs>; grant <rs type="grantNumber">AF-930627</rs> to T.K.K.; <rs type="grantNumber">AF-930351</rs>, <rs type="grantNumber">AF-939721</rs> and <rs type="grantNumber">AF-968270</rs> to K.B.); <rs type="funder">Swedish Brain Foundation (Hjärnfonden</rs>; grant <rs type="grantNumber">FO2020-0240</rs> to T.K.K.); <rs type="funder">Agneta Prytz-Folkes &amp; Gösta Folkes Foundation</rs> (grant <rs type="grantNumber">2020-00124</rs> to T.K.K.); <rs type="funder">European Union</rs>'s <rs type="programName">Horizon Europe research and innovation program</rs> (grant <rs type="grantNumber">101053962</rs> to H.Z.); <rs type="funder">Swedish State Support for Clinical Research</rs> (grant <rs type="grantNumber">ALFGBG-71320</rs> to H.Z.); <rs type="funder">Alzheimer Drug Discovery Foundation (ADDF</rs>; grant <rs type="grantNumber">201809-2016862</rs> to H.Z.); <rs type="funder">Bluefield Project</rs>, the <rs type="funder">Olav Thon Foundation</rs>, the <rs type="funder">Erling-Persson Family Foundation</rs>, <rs type="funder">Stiftelsen för Gamla Tjänarinnor</rs>, <rs type="funder">Hjärnfonden, Sweden</rs> (grant <rs type="grantNumber">FO2022-0270</rs> to H.Z.); <rs type="funder">European Union</rs>'s <rs type="programName">Horizon 2020 research and innovation program</rs> under the <rs type="grantName">Marie Skłodowska-Curie</rs> (grant <rs type="grantNumber">860197</rs> (MIRIADE) to H.Z.); the <rs type="funder">European Union Joint Program-Neurodegenerative Disease Research</rs> (grant <rs type="grantNumber">JPND2021-00694</rs> to H.Z. and <rs type="grantNumber">JPND2019-466-236</rs> to K.B.);</s><s xml:id="_PvDnyMV">The <rs type="funder">UK Dementia Research Institute at UCL</rs> (grant Article <ref type="url" target="https://doi.org/10.1038/s41591-023-02380-x">https://doi.org/10.1038/s41591-023-02380-x</ref>UKDRI-1003 to H.Z.); <rs type="funder">National Academy of Neuropsychology</rs> (grant <rs type="grantNumber">ALZ-NAN-22-928381</rs> to E.R.Z.); <rs type="funder">Fundação de Amparo a pesquisa do Rio Grande do Sul (FAPERGS</rs>; grant <rs type="grantNumber">21/2551-0000673-0</rs> to E.R.Z.); <rs type="funder">Instituto Serrapilheira</rs> (grant <rs type="grantNumber">Serra-1912-31365</rs> to E.R.Z.); <rs type="funder">Hjärnfonden</rs> (grants <rs type="grantNumber">FO2017-0243</rs> and <rs type="grantNumber">ALZ2022-0006</rs> to K.B.);</s><s xml:id="_rJwBySS">The Swedish state under the agreement between the <rs type="funder">Swedish government and the County Councils</rs>, the <rs type="funder">ALF agreement</rs> (grants <rs type="grantNumber">ALFGBG-715986</rs> and <rs type="grantNumber">ALFGBG-965240</rs> to K.B.);</s><s xml:id="_CDAD3rz">The <rs type="funder">Alzheimer's Association</rs> 2021 Zenith Award (grant ZEN-21-848495 to K.B.) and NIH, National Institute of Aging (grants AG052521 and R37 AG023651 supported the MYHAT cohort).</s><s xml:id="_QNc5NhD">Studies composing the Pittsburgh cohort were financed by NIH, National Institute of Aging (grants P30 AG066468, P01AG025204, RF1AG025516, RF1AG052525, R01AG052446 and R01AG052446).</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_yC9TC3f">
					<idno type="grant-number">R01AG075336</idno>
				</org>
				<org type="funding" xml:id="_t9Xre6q">
					<idno type="grant-number">R01AG073267</idno>
				</org>
				<org type="funding" xml:id="_RtRXZad">
					<idno type="grant-number">RF1AG053504</idno>
				</org>
				<org type="funding" xml:id="_AQJTVCU">
					<idno type="grant-number">R01AG053504</idno>
				</org>
				<org type="funding" xml:id="_m7kQUSp">
					<idno type="grant-number">RF1AG053504</idno>
				</org>
				<org type="funding" xml:id="_CsjXe4A">
					<idno type="grant-number">R01AG052528</idno>
				</org>
				<org type="funding" xml:id="_cg9HVke">
					<idno type="grant-number">P01AG14449</idno>
				</org>
				<org type="funding" xml:id="_sN5EW2D">
					<idno type="grant-number">P01AG025204</idno>
				</org>
				<org type="funding" xml:id="_DtV26nQ">
					<idno type="grant-number">R01HL105647</idno>
				</org>
				<org type="funding" xml:id="_rdYqXqr">
					<idno type="grant-number">K24HL123565</idno>
				</org>
				<org type="funding" xml:id="_Sam8wrp">
					<idno type="grant-number">AARFD-22-974627</idno>
				</org>
				<org type="funding" xml:id="_BV2Psdz">
					<idno type="grant-number">AACSF-20-648075</idno>
				</org>
				<org type="funding" xml:id="_AQHmESf">
					<idno type="grant-number">AARF-21-850325</idno>
				</org>
				<org type="funding" xml:id="_vBMrUNw">
					<idno type="grant-number">AARFD-22-923814</idno>
				</org>
				<org type="funding" xml:id="_juDpRvP">
					<idno type="grant-number">AARGD-21-850670</idno>
				</org>
				<org type="funding" xml:id="_Pw9QmNA">
					<idno type="grant-number">ADSF-21-831376-C</idno>
				</org>
				<org type="funding" xml:id="_uWmcu7Y">
					<idno type="grant-number">ADSF-21-831381-C</idno>
				</org>
				<org type="funding" xml:id="_f95jDat">
					<idno type="grant-number">ADSF-21-831377-C</idno>
				</org>
				<org type="funding" xml:id="_8xJkvy5">
					<idno type="grant-number">88887</idno>
				</org>
				<org type="funding" xml:id="_A7mgMrk">
					<idno type="grant-number">336490/2019-00</idno>
				</org>
				<org type="funding" xml:id="_YcqHrwt">
					<idno type="grant-number">200691/2021-0</idno>
				</org>
				<org type="funding" xml:id="_7FkCyhN">
					<idno type="grant-number">2020-VICO-279314</idno>
				</org>
				<org type="funding" xml:id="_ayyf6WR">
					<idno type="grant-number">MOP-11-51-31</idno>
				</org>
				<org type="funding" xml:id="_a8gEw3Q">
					<idno type="grant-number">RFN 152985</idno>
				</org>
				<org type="funding" xml:id="_fZJefN8">
					<idno type="grant-number">159815</idno>
				</org>
				<org type="funding" xml:id="_jCrgeHw">
					<idno type="grant-number">162303</idno>
				</org>
				<org type="funding" xml:id="_EEKgVju">
					<idno type="grant-number">8400707</idno>
				</org>
				<org type="funding" xml:id="_4p3YSjm">
					<idno type="grant-number">8401154</idno>
				</org>
				<org type="funding" xml:id="_QhusRD7">
					<idno type="grant-number">8401103</idno>
				</org>
				<org type="funding" xml:id="_5jPW9Jc">
					<idno type="grant-number">2021-03244</idno>
				</org>
				<org type="funding" xml:id="_8M5G2tZ">
					<idno type="grant-number">2022-01018</idno>
				</org>
				<org type="funding" xml:id="_Ky9qxm3">
					<idno type="grant-number">2017-00915</idno>
				</org>
				<org type="funding" xml:id="_gJbZzAY">
					<idno type="grant-number">2022-00732</idno>
				</org>
				<org type="funding" xml:id="_FU4PAM3">
					<idno type="grant-number">A2020812F</idno>
				</org>
				<org type="funding" xml:id="_27xY3DQ">
					<idno type="grant-number">AF-930627</idno>
				</org>
				<org type="funding" xml:id="_4sWs6m5">
					<idno type="grant-number">AF-930351</idno>
				</org>
				<org type="funding" xml:id="_963svGZ">
					<idno type="grant-number">AF-939721</idno>
				</org>
				<org type="funding" xml:id="_awuYTks">
					<idno type="grant-number">AF-968270</idno>
				</org>
				<org type="funding" xml:id="_jmXh6C2">
					<idno type="grant-number">FO2020-0240</idno>
				</org>
				<org type="funding" xml:id="_sxgxJCN">
					<idno type="grant-number">2020-00124</idno>
				</org>
				<org type="funding" xml:id="_BcW8rYN">
					<idno type="grant-number">101053962</idno>
					<orgName type="program" subtype="full">Horizon Europe research and innovation program</orgName>
				</org>
				<org type="funding" xml:id="_xCrS9dS">
					<idno type="grant-number">ALFGBG-71320</idno>
				</org>
				<org type="funding" xml:id="_qDn8VVq">
					<idno type="grant-number">201809-2016862</idno>
				</org>
				<org type="funding" xml:id="_yseP4zd">
					<idno type="grant-number">FO2022-0270</idno>
				</org>
				<org type="funding" xml:id="_dTTvYXh">
					<idno type="grant-number">860197</idno>
					<orgName type="grant-name">Marie Skłodowska-Curie</orgName>
					<orgName type="program" subtype="full">Horizon 2020 research and innovation program</orgName>
				</org>
				<org type="funding" xml:id="_KsQyYU9">
					<idno type="grant-number">JPND2021-00694</idno>
				</org>
				<org type="funding" xml:id="_q8BJ7jk">
					<idno type="grant-number">JPND2019-466-236</idno>
				</org>
				<org type="funding" xml:id="_gQuD3jx">
					<idno type="grant-number">s41591-023-02380-xUKDRI-1003</idno>
				</org>
				<org type="funding" xml:id="_EqVhEWw">
					<idno type="grant-number">ALZ-NAN-22-928381</idno>
				</org>
				<org type="funding" xml:id="_fJfbdhj">
					<idno type="grant-number">21/2551-0000673-0</idno>
				</org>
				<org type="funding" xml:id="_CSMc79M">
					<idno type="grant-number">Serra-1912-31365</idno>
				</org>
				<org type="funding" xml:id="_cxegBqj">
					<idno type="grant-number">FO2017-0243</idno>
				</org>
				<org type="funding" xml:id="_nrBbcNJ">
					<idno type="grant-number">ALZ2022-0006</idno>
				</org>
				<org type="funding" xml:id="_ZcGEvFB">
					<idno type="grant-number">ALFGBG-715986</idno>
				</org>
				<org type="funding" xml:id="_KpdBch4">
					<idno type="grant-number">ALFGBG-965240</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XxWfC9Z">Data availability</head><p xml:id="_zrCHC5E"><s xml:id="_mP9Pnkd">All requests for raw and analyzed data and materials can be sent to the corresponding author (T.A.P.) and will be promptly reviewed by the investigators and respective institutions to verify if the request is subject to any intellectual property or confidentiality obligations.</s><s xml:id="_rwvwfX9">Anonymized data will be shared upon request from a qualified academic investigator for the purpose of replicating the procedures and results presented in this article.</s><s xml:id="_NWRgebK">Any data and materials that can be shared will be released via a material transfer agreement.</s><s xml:id="_M8Vhe5c">Data are not publicly available due to information that could compromise the privacy of research participants.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gPd77Fd">Code availability</head><p xml:id="_mtkw2ua"><s xml:id="_j4yc4dQ">The codes used for the data analyses in our study can be requested from the corresponding author.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_9jtDMRn">Article</head><p xml:id="_kPfZE9s"><s xml:id="_ZfrEfFf"><ref type="url" target="https://doi.org/10.1038/s41591-023-02380-x">https://doi.org/10.1038/s41591-023-02380-x</ref></s><s xml:id="_2VNnkHd">and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.</s><s xml:id="_YVmyjDs"><ref type="bibr" target="#b7">8</ref> Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. <ref type="bibr" target="#b8">9</ref> Department of Biostatistics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 10   Geriatric Research Education and Clinical Center, VA Pittsburgh HS, Pittsburgh, PA, USA. <ref type="bibr" target="#b10">11</ref></s><s xml:id="_zNgrEk9">Department of Pharmacology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. <ref type="bibr" target="#b11">12</ref></s><s xml:id="_5KBW9Fk">Graduate Program in Biological Sciences: Pharmacology and Therapeutics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. <ref type="bibr" target="#b12">13</ref></s><s xml:id="_MM358s7">Brain Institute, PUCRS, Porto Alegre, Brazil. <ref type="bibr" target="#b13">14</ref></s><s xml:id="_umneYGa">Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. <ref type="bibr" target="#b14">15</ref></s><s xml:id="_h835smR">Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. <ref type="bibr" target="#b15">16</ref> UK Dementia Research Institute at UCL, London, UK. <ref type="bibr" target="#b16">17</ref> Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China. <ref type="bibr" target="#b17">18</ref></s><s xml:id="_hBNYCGm">Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA. <ref type="bibr" target="#b18">19</ref></s><s xml:id="_NMQKNzt">Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA. <ref type="bibr" target="#b19">20</ref></s><s xml:id="_vW4CRZ6">Department of Psychiatry, University of Illinois, Chicago, IL, USA. <ref type="bibr" target="#b20">21</ref></s><s xml:id="_G55xgQ9">Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA. <ref type="bibr" target="#b21">22</ref></s><s xml:id="_4whupcs">Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA. <ref type="bibr" target="#b22">23</ref></s><s xml:id="_PBAWfM5">Brain Imaging Centre, Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada.</s><s xml:id="_ED9B56S">e-mail: pascoalt@upmc.edu</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_atcuJac">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_6KX7sBq">Study population</head><p xml:id="_SPYSd8V"><s xml:id="_GVwKK58">This study included participants from three centers.</s><s xml:id="_8c3P4HT">The TRIAD cohort (Montreal, Canada, <ref type="url" target="https://triad.tnl-mcgill.com">https://triad.tnl-mcgill.com</ref>)</s><s xml:id="_V7yBmRq">comprised participants with a detailed clinical and cognitive assessment.</s><s xml:id="_HeT7kFZ">Exclusion criteria included inability to speak English or French; inadequate visual and auditory capacities for neuropsychological assessment; active substance abuse; major surgery; recent head trauma; medical contraindication for PET or magnetic resonance imaging; currently being enrolled in other studies and neurological, psychiatric or systemic comorbidities that were not adequately treated with a stable medication regimen.</s><s xml:id="_Hcj6N6x">CU individuals had a CDR = 0 and no objective cognitive impairment.</s><s xml:id="_W5Jnmh9">The study was approved by the Douglas Mental Health University Institute Research Ethics Board and Montreal Neurological Institute PET working committee, and all participants provided written informed consent.</s></p><p xml:id="_cw4g4PD"><s xml:id="_HdqkBrb">The MYHAT is a population-based study cohort drawn from a Rust Belt region of southwestern Pennsylvania, USA <ref type="bibr" target="#b34">35</ref> .</s><s xml:id="_aWF6kf7">Participants were selected by age-stratified random sampling from the publicly available voter registration lists over the following two time periods: 2006-2008 and 2016-2019.</s><s xml:id="_2VvW6e8">Inclusion criteria at study entry included the following: (1) 65+ years old, (2) living in a designated town, (3) not residing in long-term care settings, (4) having sufficient hearing and vision to complete neuropsychological testing and (5) having decisional capacity.</s><s xml:id="_YHjVakq">CU individuals had CDR = 0.</s><s xml:id="_N8DXNya">All study procedures were approved by the University of Pittsburgh Institutional Review Board, and all participants provided written informed consent.</s></p><p xml:id="_gd5SH2p"><s xml:id="_txdgpfC">The Pittsburgh cohort is composed of research volunteers from the following four studies conducted at the University of Pittsburgh: the Heart Strategies Concentrating on Risk Evaluation parent study <ref type="bibr" target="#b35">36</ref> , the Human Connectome Project <ref type="bibr" target="#b36">37</ref> , the Normal Aging study <ref type="bibr" target="#b37">38</ref> and the MsBrain study <ref type="bibr" target="#b38">39</ref> .</s><s xml:id="_yQY48vm">All individuals provided written informed consent to one of the above studies.</s><s xml:id="_rejb5rX">CU individuals were classified using either CDR = 0 or Montreal Cognitive Assessment (MoCA) &gt;25 (for the MsBrain study).</s><s xml:id="_p8V24Be">Individuals were selected according to cognitive status and plasma biomarker availability.</s><s xml:id="_FcBfbpm">Details of each cohort recruitment are reported in Supplementary Table <ref type="table">6</ref>.</s><s xml:id="_M97PV6W">All study procedures were approved by the University of Pittsburgh Institutional Review Board, and all participants provided written informed consent.</s></p><p xml:id="_77RYTZt"><s xml:id="_9tnV7uh">Participants from all cohorts received compensation commensurate with the number of study procedures completed and the duration of participation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Y8nARKG">Plasma and CSF biomarkers</head><p xml:id="_cpNbbBR"><s xml:id="_3S79SDR">For Pittsburgh and TRIAD cohorts, plasma biomarkers (except for plasma p-tau217) were measured using single-molecule array (Simoa) methods on an HD-X Automated Immunoassay Analyzer (Quanterix), at the Clinical Neurochemistry Laboratory at the University of Gothenburg.</s><s xml:id="_HJn8nzM">Plasma Aβ42, Aβ40, GFAP and neurofilament light were quantified with the Neurology 4-Plex E (103670) commercial assays from Quanterix.</s><s xml:id="_rEzYqRx">Plasma p-tau181 (ref.</s><s xml:id="_b3tj2ca">40) and plasma p-tau231 (ref.</s><s xml:id="_rWtQGn3">41) were measured using an in-house Simoa assay developed at the University of Gothenburg, as previously described.</s><s xml:id="_WR2yCvw">Plasma p-tau217 (available only for TRIAD) was quantified by scientists at Janssen Research &amp; Development <ref type="bibr" target="#b41">42</ref> .</s><s xml:id="_V4nwKtr">For the MYHAT cohort, plasma biomarkers were measured using Simoa methods on an HD-X instrument (Quanterix), at the Department of Psychiatry, University of Pittsburgh School of Medicine.</s><s xml:id="_gNyV7dE">Plasma p-tau181 was measured with the p-tau181 V2 Advantage (103714), whereas plasma Aβ42, Aβ40, GFAP and neurofilament light concentrations were measured with the Neurology 4-Plex E (103670) commercial assays from Quanterix.</s><s xml:id="_uT7rTem">For cohorts with no available Aβ-PET (that is, MYHAT and Pittsburgh cohorts), Aβ positivity was determined using plasma Aβ42/40 based on the expected 30% of Aβ positivity in CU individuals <ref type="bibr" target="#b42">43</ref> .</s><s xml:id="_EM6ucyT">As younger individuals are more likely to be devoid of AD-related pathology <ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b44">45</ref> , cutoffs for astrocyte reactivity were generated using the plasma GFAP concentration mean of the 15% youngest Aβ-negative individuals plus 2 s.d.</s><s xml:id="_j7y3EDe">Sensitivity analyses using multiple cutoffs to define Aβ positivity or astrocyte positivity can be found in Supplementary Fig. <ref type="figure">2</ref> and Extended Data Table <ref type="table">2</ref>. CSF sTREM2 was measured using a Meso-Scale Discovery assay in a subsample in the TRIAD cohort, and the cutoff for positivity was set to correspond to the same percentile of GFAP positivity <ref type="bibr" target="#b45">46</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JENP7qF">Magnetic resonance imaging/PET biomarkers</head><p xml:id="_WZqnanD"><s xml:id="_ZFnDVBh">For the TRIAD cohort, Aβ-PET was quantified using the tracer ( 18 F) AZD4694 and tau-PET with the tracer ( 18 F)MK-6240 in a Siemens high-resolution research tomograph.</s><s xml:id="_BZhjjJN">( 18 F)AZD4694 and ( 18 F)MK-6240 images were acquired at 40-70 min and 90-110 min postinjection, respectively.</s><s xml:id="_JcTP9Zt">Standardized uptake value ratio (SUVR) was calculated using the whole cerebellum gray matter for ( 18 F)AZD4694 and inferior cerebellum gray matter ( 18 F)MK-6240 as the reference tissue.</s><s xml:id="_qYWuNnE">Neocortical ( 18 F)AZD4694 SUVR value was estimated from a cortical composite, including the precuneus, prefrontal, orbitofrontal, parietal, temporal, anterior and posterior cingulate cortices.</s><s xml:id="_YmatyTM">Individuals with Aβ-PET neocortical SUVR &gt; 1.55 were considered Aβ-positive <ref type="bibr" target="#b46">47</ref> .</s><s xml:id="_V6EMxYn">A subsample of 71 CU individuals had a follow-up ( 18 F)MK-6240 with a mean of 2.3 years after baseline.</s><s xml:id="_YHE5N3C">Tau-PET Braak stage segmentation has been previously described <ref type="bibr" target="#b47">48</ref> .</s><s xml:id="_bTeJcty">Stages consisted of the following regions: Braak I (transentorhinal), Braak II (entorhinal and hippocampus), Braak III (amygdala, parahippocampal gyrus, fusiform gyrus and lingual gyrus), Braak IV (insula, inferior temporal, lateral temporal, posterior cingulate and inferior parietal), Braak V (orbitofrontal, superior temporal, inferior frontal, cuneus, anterior cingulate, supramarginal gyrus, lateral occipital, precuneus, superior parietal, superior frontal and rostromedial frontal) and Braak VI (paracentral, postcentral, precentral and pericalcarine).</s></p><p xml:id="_Gxzptac"><s xml:id="_M4Zqspx">A subset of individuals from the MYHAT (n = 86) and Pittsburgh (n = 64) cohorts had Aβ-PET available for this study.</s><s xml:id="_MUSDKNp">For these individuals, Aβ-PET was quantified using ( 11 C)PiB PET acquired at 50-70 min postinjection.</s><s xml:id="_J3TbDHw">A global ( 11 C)PiB SUVR index was computed by volume-weighted averaging of all nine composite ( 11 C)PiB regions (anterior cingulate, posterior cingulate, insula, superior frontal cortex, orbitofrontal cortex, lateral temporal cortex, parietal, precuneus and ventral striatum).</s><s xml:id="_29v3e4C">Aβ-PET positivity was defined using a previously established cutoff <ref type="bibr" target="#b48">49</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_VSU3Mjy">Statistical analysis</head><p xml:id="_qAEmGQw"><s xml:id="_9grNY97">Neuroimaging analyses were carried out using the VoxelStats toolbox version 1 (<ref type="url" target="https://github.com/sulantha2006/VoxelStats">https://github.com/sulantha2006/VoxelStats</ref>),</s><s xml:id="_Cw8qyCM">a MATLABbased analytical framework that allows for the execution of multimodal voxel-wise neuroimaging analyses <ref type="bibr" target="#b49">50</ref> and an R Package for Medical Imaging NetCD (RMINC) v1.5.3.0.</s><s xml:id="_RMy64kF">Other statistical analyses were performed using the R Statistical Software Package version 3.5.3.</s><s xml:id="_w8qXyG6">Differences between groups in continuous variables (age, cognitive performance (mini-mental state exam (MMSE) or MoCA), biomarkers for Aβ, plasma GFAP, p-tau epitopes and neurofilament light) were assessed using analysis of variance with Tukey correction.</s><s xml:id="_nXcTtEM">Kruskal-Wallis with post hoc Mann-Whitney U tests were used for categorical or ordinal variables (sex and APOE ε4 status).</s><s xml:id="_8dBr8JY">For modeling the trajectories of plasma p-tau epitopes as a function of Aβ burden (plasma Aβ or Aβ-PET), we corrected each plasma p-tau epitope value by age and sex.</s><s xml:id="_MVxpgJk">Individuals in the 15th lower percentile for Aβ-PET or the 15th highest percentile for plasma Aβ42/40 were used as anchors to z scores.</s><s xml:id="_X6JGUNd">Then, we applied a robust linear regression method (Lowess), using 1,000 robustifying iterations, with a smoother span of 0.95.</s><s xml:id="_AhA25Ux">The effect size of groups (Aβ + , Ast + and Aβ + /Ast + ) in relation to Aβ -/Ast -was estimated using Cohen's d, in which the dependent variable was the plasma p-tau biomarkers corrected for age and sex (Ast + group included individuals positive for astrocyte reactivity but Aβ -, whereas the Aβ + group included individuals positive for Aβ but Ast -).</s><s xml:id="_fvkW33E">The associations between biomarkers</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_EBVxcYh">Reporting summary</head><p xml:id="_UfJYWy5"><s xml:id="_MgtCAbJ">Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.</s><s xml:id="_mpudXhy">Program (outside submitted work).</s><s xml:id="_zm3g29F">K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics and Siemens Healthineers and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper.</s><s xml:id="_7YNKxwE">S.G. has served as a scientific advisor to Cerveau Therapeutics.</s><s xml:id="_edCjG3D">E.R.Z.</s><s xml:id="_HwZdJm9">serves on the scientific advisory board of Next Innovative Therapeutics (Nintx).</s><s xml:id="_jDaUpXg">P.R.-N.</s><s xml:id="_u97ZKJU">has served on scientific advisory boards and/or as a consultant for Eisai, Novo Nordisk and Roche.</s><s xml:id="_bZHFm4J">N.J.A. has given lectures in symposia sponsored by Lilly and Quanterix.</s><s xml:id="_rPvj7EH">M.D.I. has received research funding from GE Healthcare and Avid Radiopharmaceuticals. R.C.T. serves as a consultant, advisor and/or on the medical advisory board of Happify Health, Astellas Pharma, Bayer and Hello Therapeutics.</s><s xml:id="_Nct4dpR">GE Healthcare holds a license agreement with the University of Pittsburgh based on the PiB PET technology described in this paper.</s><s xml:id="_aZNyVTK">W.E.K. is a co-inventor of PiB and, as such, has a financial interest in this license agreement.</s><s xml:id="_UmNPQNY">GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of this paper.</s><s xml:id="_AD8Zry3">The other authors declare no competing interests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_mhaWJQX">Author contributions</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vjdxD6U">Additional information</head><p xml:id="_BTnN8aY"><s xml:id="_nkGGzFn">Extended data is available for this paper at <ref type="url" target="https://doi.org/10.1038/s41591-023-02380-x">https://doi.org/10.1038/s41591-023-02380-x</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_tNkNwrr">Supplementary information</head><p xml:id="_d42BKfF"><s xml:id="_tZ3Ckh6">The online version contains supplementary material available at <ref type="url" target="https://doi.org/10.1038/s41591-023-02380-x">https://doi.org/10.1038/s41591-023-02380-x</ref>.</s></p><p xml:id="_cfNdtKD"><s xml:id="_vSuFTxn">Correspondence and requests for materials should be addressed to Tharick A. Pascoal.</s><s xml:id="_38k2HkE">for astrocyte reactivity.</s><s xml:id="_TnfRGBD">The plots show regression line with their respective 95% confidence intervals and the p-values were adjusted by age and sex.</s><s xml:id="_2kP2N2j">In addition, a plasma Aβ burden × sex interaction was also computed.</s><s xml:id="_7gDaA82">Orange lines and dots represent women and green lines and dots represent men.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2FjFvEd">Peer review information</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_HZQ6EUc">Extended Data Table 1 | Associations between plasma p-tau181 and Aβ burden according to astrocyte reactivity status</head><p xml:id="_nnu4xpb"><s xml:id="_HYyx4au">Abbreviations: Ast-: reactive astrocyte negative; Ast+: reactive astrocyte positive; p-tau: phosphorylated tau.</s><s xml:id="_p5wNRDa">We inverted the values for plasma Aβ ratio in the analysis to pool plasma Aβ and Aβ-PET levels together.</s><s xml:id="_GZ3GtqY">Covariates: age, sex, and cohort (when all studies were evaluated together).</s><s xml:id="_CZFPsMy">P-values were computed using linear regression models adjusted by age, sex, and cohort (when appropriate) for individuals classified as Ast-and Ast+.</s><s xml:id="_4JDTvG6">In addition, the Aβ burden × astrocyte reactivity status interaction was also computed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_eZeVX3C">Extended Data Table 2 | Sensitivity analyses using multiple plasma GFAP cutoffs to determine astrocyte positivity</head><p xml:id="_qxX3hkb"><s xml:id="_VHqF9n9">Abbreviations: Ast-: reactive astrocyte negative; Ast+: reactive astrocyte positive; GFAP: glial fibrillary acidic protein; s.d.: standard deviation; p-tau: phosphorylated tau.</s><s xml:id="_PFXuzdM">The highest β-estimate was obtained using GFAP cutoff calculated as the mean + 2.0 s.d. of controls devoid of Aβ pathology for all plasma p-tau epitopes.</s><s xml:id="_HRZCjGF">Covariates: age, sex, and cohort.</s><s xml:id="_Jp2bKCJ">We inverted the values for plasma Aβ ratio in the analysis to pool plasma Aβ and Aβ-PET levels together.</s><s xml:id="_rCJkt4P">P-values were computed using linear regression models adjusted by age, sex and cohort (when appropriate) for individuals classified as Ast-and Ast+.</s><s xml:id="_YutwvPR">In addition, the Aβ burden × astrocyte reactivity status interaction was also computed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_rMQRh56">Extended Data Table 3 | Sensitivity analysis adjusting for APOEε4 status</head><p xml:id="_98mqAXB"><s xml:id="_z8u8XyB">Abbreviations: Ast-: reactive astrocyte negative; Ast+: reactive astrocyte positive; p-tau: phosphorylated tau.</s><s xml:id="_27k5RQD">We inverted the values for plasma Aβ ratio in the analysis to pool plasma Aβ and Aβ-PET levels together.</s><s xml:id="_TwRtRE9">P-values were computed using linear regression models adjusted by age, sex and cohort (when appropriate) for individuals classifies as Ast-and Ast+.</s><s xml:id="_WhJYHGb">In addition, the Aβ burden × astrocyte reactivity status interaction was also computed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_aHRYNpU">Extended Data Table 4 | Associations between plasma p-tau231 and p-tau217 and Aβ burden according to astrocyte reactivity status</head><p xml:id="_A6yrXWy"><s xml:id="_aZRncKh">Abbreviations: Ast-: reactive astrocyte negative; Ast+: reactive astrocyte positive; p-tau: phosphorylated tau.</s><s xml:id="_3QnCN3g">Covariates: age, sex, and cohort.</s><s xml:id="_ae4y32W">We inverted the values for plasma Aβ ratio in the analysis to pool plasma Aβ and Aβ-PET levels together.</s><s xml:id="_vBmKKU4">P-values were computed using linear regression models adjusted by age, sex and cohort (when appropriate) for individuals classifies as Ast-and Ast+.</s><s xml:id="_MRaFC9Q">In addition, the Aβ burden × astrocyte reactivity status interaction was also computed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_b39ZGvM">Extended Data Table 5 | Associations between plasma p-tau and Aβ burden according to microglial activation (MA) status in the TRIAD cohort</head><p xml:id="_73Sb5cv"><s xml:id="_wm2kJpA">Abbreviations: MA-: microglial activation negative; MA+: microglial activation positive; p-tau: phosphorylated tau.</s><s xml:id="_m2XXm3n">Covariates: age and sex.</s><s xml:id="_XtRmGPp">The effect of astrocyte reactivity in this subpopulation remained significant (Aβ burden × Astrocyte positivity status: β = 0.50, 95% CI = 0.15-0.85;</s><s xml:id="_fzBFsEW">t-value = 2.87; p-value = 0.006).</s><s xml:id="_XaTd4Us">P-values were computed using linear regression models adjusted by age, sex and cohort (when appropriate) for individuals classifies as MA-and MA+.</s><s xml:id="_PJRFUYa">In addition, the Aβ burden × microglial activation status interaction was also computed.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_xs7RZfv">Tracking pathophysiological processes in Alzheimer&apos;s disease: an updated hypothetical model of dynamic biomarkers</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jack</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4hbc32a">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="207" to="216" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jack, C. R. Jr et al. Tracking pathophysiological processes in Alzheimer&apos;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216 (2013).</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_YxaWXpf">Biomarkers for neurodegenerative diseases</title>
		<author>
			<persName><forename type="first">O</forename><surname>Hansson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4cc8mWV">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="954" to="963" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954-963 (2021).</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_N5fw657">Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Milà-Alomà</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vq5BZP4">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1797" to="1801" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Milà-Alomà, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer&apos;s disease. Nat. Med. 28, 1797-1801 (2022).</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_yww9Jpt">Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Hanseeuw</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41591-023-02380-x</idno>
		<ptr target="https://doi.org/10.1038/s41591-023-02380-x" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_PpKs8w3">JAMA Neurol</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="915" to="924" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hanseeuw, B. J. et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 76, 915-924 (2019). Article https://doi.org/10.1038/s41591-023-02380-x</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_txH5z3h">Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ossenkoppele</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamaneurol.2021.1858</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pjvgfTA">JAMA Neurol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="961" to="971" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ossenkoppele, R. et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 78, 961-971 (2021).</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_eZPtQ3X">Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ossenkoppele</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41591-022-02049-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3GAknQg">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2381" to="2387" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381-2387 (2022).</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_FYS2kJw">Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Roberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_E4eFSxp">JAMA Neurol</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="970" to="979" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roberts, R. O. et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol. 75, 970-979 (2018).</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_kCw6Tcd">Characterizing amyloid-positive individuals with normal tau PET levels after 5 years: an ADNI study</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Josephs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Weigand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Whitwell</surname></persName>
		</author>
		<idno type="DOI">10.1212/wnl.0000000000200287</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MMxhMXj">Neurology</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="2282" to="e2292" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Josephs, K. A., Weigand, S. D. &amp; Whitwell, J. L. Characterizing amyloid-positive individuals with normal tau PET levels after 5 years: an ADNI study. Neurology 98, e2282-e2292 (2022).</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_Cq6CPr8">Dementia in 2014. Towards early diagnosis in Alzheimer disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nordberg</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrneurol.2014.257</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PgwYMBH">Nat. Rev. Neurol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="69" to="70" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nordberg, A. Dementia in 2014. Towards early diagnosis in Alzheimer disease. Nat. Rev. Neurol. 11, 69-70 (2015).</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_QdpVxTZ">Toward defining the preclinical stages of Alzheimer&apos;s disease: recommendations from the National Institute on Aging-Alzheimer&apos;s Association workgroups on diagnostic guidelines for Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Sperling</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jalz.2011.03.003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_J6KAcRm">Alzheimers Dement</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="280" to="292" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer&apos;s disease: recommendations from the National Institute on Aging-Alzheimer&apos;s Association workgroups on diagnostic guidelines for Alzheimer&apos;s disease. Alzheimers Dement. 7, 280-292 (2011).</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_bstnGjz">Early association of reactive astrocytes with senile plaques in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Pike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Cummings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Cotman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_72NqNKV">Exp. Neurol</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="172" to="179" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pike, C. J., Cummings, B. J. &amp; Cotman, C. W. Early association of reactive astrocytes with senile plaques in Alzheimer&apos;s disease. Exp. Neurol. 132, 172-179 (1995).</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_ebr3fEz">Patterns of gliosis in Alzheimer&apos;s disease and aging cerebrum</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Beach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Mcgeer</surname></persName>
		</author>
		<idno type="DOI">10.1002/glia.440020605</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3fJTrmm">Glia</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="420" to="436" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Beach, T. G., Walker, R. &amp; McGeer, E. G. Patterns of gliosis in Alzheimer&apos;s disease and aging cerebrum. Glia 2, 420-436 (1989).</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_sENWVZY">Reactive astrocyte nomenclature, definitions, and future directions</title>
		<author>
			<persName><forename type="first">C</forename><surname>Escartin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gc7n6AJ">Nat. Neurosci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="312" to="325" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Escartin, C. et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 24, 312-325 (2021).</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_aF6dpyC">Reactive astrogliosis: a friend or foe in the pathogenesis of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Fontana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nordberg</surname></persName>
		</author>
		<idno type="DOI">10.1111/jnc.15565</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZxcEvQ4">J. Neurochem</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="309" to="324" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kumar, A., Fontana, I. C. &amp; Nordberg, A. Reactive astrogliosis: a friend or foe in the pathogenesis of Alzheimer&apos;s disease. J. Neurochem. 164, 309-324 (2023).</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_dzegEDf">Meta-analysis of human prefrontal cortex reveals activation of GFAP and decline of synaptic transmission in the aging brain</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wruck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Adjaye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fZ4VsFy">Acta Neuropathol. Commun</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">26</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wruck, W. &amp; Adjaye, J. Meta-analysis of human prefrontal cortex reveals activation of GFAP and decline of synaptic transmission in the aging brain. Acta Neuropathol. Commun. 8, 26 (2020).</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_ZFrY8Aq">Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Garwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Pooler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Atherton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Hanger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Noble</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QwqV7NT">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">167</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Garwood, C. J., Pooler, A. M., Atherton, J., Hanger, D. P. &amp; Noble, W. Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis. 2, e167 (2011).</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_HKwmaBb">Astrocytic α2-Na + /K + ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Mann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_X3zfRWj">Sci. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">4107</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mann, C. N. et al. Astrocytic α2-Na + /K + ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model. Sci. Transl. Med. 14, eabm4107 (2022).</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_ZBSDC35">Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Litvinchuk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DRy5EbW">Neuron</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="1337" to="1353" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Litvinchuk, A. et al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer&apos;s disease. Neuron 100, 1337-1353 (2018).</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_VmFNngD">Propagation of tau pathology in a model of early Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>De Calignon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wFfqxFU">Neuron</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="685" to="697" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">de Calignon, A. et al. Propagation of tau pathology in a model of early Alzheimer&apos;s disease. Neuron 73, 685-697 (2012).</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_B9mckYd">Filamentous recombinant human tau activates primary astrocytes via an integrin receptor complex</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ye</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-020-20322-w</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bGHeFpP">Nat. Commun</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">95</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang, P. &amp; Ye, Y. Filamentous recombinant human tau activates primary astrocytes via an integrin receptor complex. Nat. Commun. 12, 95 (2021).</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_9NKXVt9">Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Benedet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EZTwbbb">JAMA Neurol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="1471" to="1483" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Benedet, A. L. et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 78, 1471-1483 (2021).</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_fYQT783">Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">P</forename><surname>Chatterjee</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41398-020-01137-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kP7Zq7u">Transl. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">27</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chatterjee, P. et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer&apos;s disease. Transl. Psychiatry 11, 27 (2021).</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_YQ3msFT">Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Pereira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_94DpvGY">Brain</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="3505" to="3516" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pereira, J. B. et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer&apos;s disease. Brain 144, 3505-3516 (2021).</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_PrgaF29">Plasma glial fibrillary acidic protein is associated with 18F-SMBT-1 PET: two putative astrocyte reactivity biomarkers for Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">P</forename><surname>Chatterjee</surname></persName>
		</author>
		<idno type="DOI">10.3233/jad-220908</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DsqBF97">J. Alzheimers Dis</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="615" to="628" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chatterjee, P. et al. Plasma glial fibrillary acidic protein is associated with 18F-SMBT-1 PET: two putative astrocyte reactivity biomarkers for Alzheimer&apos;s disease. J. Alzheimers Dis. 92, 615-628 (2023).</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_FcVPu3d">Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity</title>
		<author>
			<persName><forename type="first">S</forename><surname>Palmqvist</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-017-01150-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UBadDun">Nat. Commun</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">1214</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Palmqvist, S. et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 8, 1214 (2017).</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_PzDtnjD">Neuropathological stageing of Alzheimer-related changes</title>
		<author>
			<persName><forename type="first">H</forename><surname>Braak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Braak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MNdBJUn">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="239" to="259" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Braak, H. &amp; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991).</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_uV7taPD">NIA-AA research framework: toward a biological definition of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jack</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CsW6Dbz">Alzheimers Dement</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="535" to="562" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jack, C. R. Jr et al. NIA-AA research framework: toward a biological definition of Alzheimer&apos;s disease. Alzheimers Dement. 14, 535-562 (2018).</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_MAepvEJ">Plasma biomarker profiles in autosomal dominant Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">C</forename><surname>Johansson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Z59StwQ">Brain</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="1132" to="1140" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Johansson, C. et al. Plasma biomarker profiles in autosomal dominant Alzheimer&apos;s disease. Brain 146, 1132-1140 (2023).</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_FewWy5F">Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M W</forename><surname>Verberk</surname></persName>
		</author>
		<idno type="DOI">10.1016/s2666-7568(20)30061-1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NnnbJfb">Lancet Healthy Longev</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="87" to="e95" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Verberk, I. M. W. et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2, e87-e95 (2021).</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_5wBmbEj">Plasma glial fibrillary acidic protein in the Alzheimer disease continuum: relationship to other biomarkers, differential diagnosis, and prediction of clinical progression</title>
		<author>
			<persName><forename type="first">X.-N</forename><surname>Shen</surname></persName>
		</author>
		<idno type="DOI">10.1093/clinchem/hvad018</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tZr98rd">Clin. Chem</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="411" to="421" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shen, X.-N. et al. Plasma glial fibrillary acidic protein in the Alzheimer disease continuum: relationship to other biomarkers, differential diagnosis, and prediction of clinical progression. Clin. Chem. 69, 411-421 (2023).</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_rNDXF8J">Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Buckley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9GVeTHJ">JAMA Neurol</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="542" to="551" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Buckley, R. F. et al. Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol. 76, 542-551 (2019).</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_TKY7yqM">Sex differences in in vivo tau neuropathology in a multiethnic sample of late middle-aged adults</title>
		<author>
			<persName><forename type="first">P</forename><surname>Palta</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.neurobiolaging.2021.03.007</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CkVvake">Neurobiol. Aging</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="109" to="116" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Palta, P. et al. Sex differences in in vivo tau neuropathology in a multiethnic sample of late middle-aged adults. Neurobiol. Aging 103, 109-116 (2021).</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_FabHFj7">Sex differences in plasma p-tau181 associations with Alzheimer&apos;s disease biomarkers, cognitive decline, and clinical progression</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Tsiknia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_dJDwBKe">Mol. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="4314" to="4322" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tsiknia, A. A. et al. Sex differences in plasma p-tau181 associations with Alzheimer&apos;s disease biomarkers, cognitive decline, and clinical progression. Mol. Psychiatry 27, 4314-4322 (2022).</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_tVn75VQ">Lecanemab in early Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Van Dyck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hY7mGXA">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">388</biblScope>
			<biblScope unit="page" from="9" to="21" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note>References</note>
	<note type="raw_reference">van Dyck, C. H. et al. Lecanemab in early Alzheimer&apos;s disease. N. Engl. J. Med. 388, 9-21 (2023). References</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_M4HTVb9">Prevalence of mild cognitive impairment by multiple classifications: the Monongahela-Youghiogheny Healthy Aging Team (MYHAT) project</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ganguli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zGUqKmb">Am. J. Geriatr. Psychiatry</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="674" to="683" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ganguli, M. et al. Prevalence of mild cognitive impairment by multiple classifications: the Monongahela-Youghiogheny Healthy Aging Team (MYHAT) project. Am. J. Geriatr. Psychiatry 18, 674-683 (2010).</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_rT8zh6x">Low prevalence of &quot;ideal cardiovascular health&quot; in a community-based population: the heart strategies concentrating on risk evaluation (Heart SCORE) study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Bambs</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.110.980151</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8g7d8sy">Circulation</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="850" to="857" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bambs, C. et al. Low prevalence of &quot;ideal cardiovascular health&quot; in a community-based population: the heart strategies concentrating on risk evaluation (Heart SCORE) study. Circulation 123, 850-857 (2011).</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_d9vShuQ">Connectomics in brain aging and dementiathe background and design of a study of a connectome related to human disease</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Cohen</surname></persName>
		</author>
		<idno type="DOI">10.3389/fnagi.2021.669490</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xgSjncf">Front. Aging Neurosci</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">669490</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cohen, A. D. et al. Connectomics in brain aging and dementia- the background and design of a study of a connectome related to human disease. Front. Aging Neurosci. 13, 669490 (2021).</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_KEtAMUH">Frequent amyloid deposition without significant cognitive impairment among the elderly</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Aizenstein</surname></persName>
		</author>
		<idno type="DOI">10.1001/archneur.65.11.1509</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ra3uHD6">Arch. Neurol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1509" to="1517" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aizenstein, H. J. et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65, 1509-1517 (2008).</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_RktN8KM">Menopausal vasomotor symptoms and white matter hyperintensities in midlife women</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Thurston</surname></persName>
		</author>
		<idno type="DOI">10.1212/wnl.0000000000201401</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6QeQZjM">Neurology</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="133" to="e141" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thurston, R. C. et al. Menopausal vasomotor symptoms and white matter hyperintensities in midlife women. Neurology 100, e133- e141 (2023).</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_rq9Eebb">Blood phosphorylated tau 181 as a biomarker for Alzheimer&apos;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Karikari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_p6K9XCm">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="422" to="433" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer&apos;s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422-433 (2020).</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_XRt5UXz">Plasma p-tau231: a new biomarker for incipient Alzheimer&apos;s disease pathology</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Ashton</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00401-021-02275-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_G2jqjGD">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="709" to="724" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ashton, N. J. et al. Plasma p-tau231: a new biomarker for incipient Alzheimer&apos;s disease pathology. Acta Neuropathol. 141, 709-724 (2021).</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_Qd3rtvk">Development and validation of a high-sensitivity assay for measuring p217+tau in plasma</title>
		<author>
			<persName><forename type="first">G</forename><surname>Triana-Baltzer</surname></persName>
		</author>
		<idno type="DOI">10.1002/dad2.12204</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WQPc5Pt">Alzheimers Dement. (Amst.)</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">12204</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Triana-Baltzer, G. et al. Development and validation of a high-sensitivity assay for measuring p217+tau in plasma. Alzheimers Dement. (Amst.) 13, e12204 (2021).</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_GFuDuQZ">Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ossenkoppele</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_PYcR8PA">JAMA</title>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="page" from="1939" to="1949" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ossenkoppele, R. et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313, 1939-1949 (2015).</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_W28FK77">Defining imaging biomarker cut points for brain aging and Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jack</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JnqX4VN">Alzheimers Dement</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="205" to="216" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jack, C. R. Jr. et al. Defining imaging biomarker cut points for brain aging and Alzheimer&apos;s disease. Alzheimers Dement. 13, 205-216 (2017).</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_s9w4rPH">The evolution of the reference value concept</title>
		<author>
			<persName><forename type="first">R</forename><surname>Gräsbeck</surname></persName>
		</author>
		<idno type="DOI">10.1515/cclm.2004.118</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RSzDGEQ">Clin. Chem. Lab. Med</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="692" to="697" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gräsbeck, R. The evolution of the reference value concept. Clin. Chem. Lab. Med. 42, 692-697 (2004).</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_xr8uVQz">Exercise as a potential modulator of inflammation in patients with Alzheimer&apos;s disease measured in cerebrospinal fluid and plasma</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Jensen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.exger.2019.04.003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6yk8KKh">Exp. Gerontol</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="91" to="98" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jensen, C. S. et al. Exercise as a potential modulator of inflammation in patients with Alzheimer&apos;s disease measured in cerebrospinal fluid and plasma. Exp. Gerontol. 121, 91-98 (2019).</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_QEWujWT">Determining amyloid-β positivity using (18) F-AZD4694 PET imaging</title>
		<author>
			<persName><forename type="first">J</forename><surname>Therriault</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vf3Shdt">J. Nucl. Med</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="247" to="252" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Therriault, J. et al. Determining amyloid-β positivity using (18) F-AZD4694 PET imaging. J. Nucl. Med. 62, 247-252 (2021).</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_ehGC7Fc">F-MK-6240 PET for early and late detection of neurofibrillary tangles</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Pascoal</surname></persName>
		</author>
		<idno type="DOI">10.1093/brain/awaa180</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FTTTF3G">Brain</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="2818" to="2830" />
			<date type="published" when="2020">18. 2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pascoal, T. A. et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143, 2818-2830 (2020).</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_C4GUwTS">Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Cohen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.neuroimage.2013.01.015</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_QvtwSGs">Neuroimage</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="207" to="215" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cohen, A. D. et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage 71, 207-215 (2013).</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_3n8SscH">VoxelStats: a MATLAB package for multi-modal voxel-wise brain image analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mathotaarachchi</surname></persName>
		</author>
		<idno type="DOI">10.3389/fninf.2016.00020</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nY3SJvv">Front. Neuroinform</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">20</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mathotaarachchi, S. et al. VoxelStats: a MATLAB package for multi-modal voxel-wise brain image analysis. Front. Neuroinform. 10, 20 (2016).</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_u3Dszum">Unified univariate and multivariate random field theory</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Worsley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tomaiuolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lerch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EN4XPNb">Neuroimage</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="189" to="S195" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Worsley, K. J., Taylor, J. E., Tomaiuolo, F. &amp; Lerch, J. Unified univariate and multivariate random field theory. Neuroimage 23, S189-S195 (2004).</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
